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Executive summary 
In Africa, tuberculosis (TB) is the most 
common cause of death from a curable 
infectious disease. The nutritional conse­
quences of active TB are well recognized by 
clinicians, yet little is known about effective 
nutritional management, nor of the interac­
tions between TB treatment and nutritional 
status. The purpose of this paper is to 
review the scientific literature on the role 
of nutrition in TB disease, summarize key 
findings and knowledge gaps, and investi­
gate related programmatic experience. The 
primary target audiences for this review are 
nutrition program managers in Africa and 
technical advisors in TB programs. 
Based on the information summarized in 
this report, it is clear that TB affects nutri­
tional status. Many patients with active TB 
experience severe weight loss and some 
show signs of vitamin and mineral deficien­
cies. Persons with TB/HIV co-infection 
are even worse off nutritionally. However, 
the evidence surrounding best practices for 
nutritional management is very limited. 
The paper concludes with suggested 
approaches for addressing the nutritional 
needs of patients with active TB, based 
on nutritional principles and experience. 
Research priorities to provide the type of 
evidence needed to translate these sugges­
tions into firmer evidence-based recom­
mendations are also listed. 
Generalized malnutrition and TB 
The association between TB and malnu­
trition has long been known. TB makes 
malnutrition worse and malnutrition 
weakens immunity, thereby increasing the 
likelihood that latent TB will develop into 
active disease. Unfortunately, few studies 
have been designed to examine the relation­
ship between nutrition and the incidence of 
TB or its severity. It is very difficult to deter­
mine accurately what the nutritional status 
of individuals with active TB was before 
the onset of the disease, making it impos­
sible to determine whether malnutrition led 
to advancement of the disease or whether 
active TB led to malnutrition. Several studies 
report that patients with active TB are more 
likely to be wasted or have a lower body mass 
index (BMI = kg/m2) than healthy controls 
and that wasting is associated with increased 
mortality in TB patients. 
TB affects protein metabolism and nutri­
tional status through multiple mechanisms. 
With anti-TB drug treatment, nutritional 
status usually improves. This may be for 
a variety of reasons, including improved 
appetite and food intake, reduced energy/ 
nutrient demands, and improved metabolic 
efficiency. However, most improvements 
are limited to increases in fat mass with 
little effect on muscle tissue. The evidence 
suggests that adequate nutritional intake 
during TB care and recovery is needed to 
fully restore nutritional status during and 
following TB treatment and microbial 
cure. There are few published studies on 
the optimum duration and effectiveness of 
nutritional support during and following TB 
treatment. 
HIV is one of the most important factors 
contributing to the increase in active TB 
cases in sub-Saharan Africa. HIV infec­
tion increases the risk of rapid TB disease 
progression. Co-infection with HIV and 
TB poses an additional metabolic, physical, 
and nutritional burden, resulting in further 
increase in energy expenditure, malabsorp­
tion, and micronutrient deficiency. There is 
evidence that adults and children co-infected 
with HIV and TB are at greatest risk of 
malnutrition, poor treatment outcomes, 
and death. Efforts to prevent, manage, and 
treat HIV and TB have been largely separate 
endeavors, despite the overlapping epidemi­
ology. Continued and improved collabora­
tion between TB and HIV/AIDS programs 
is necessary to control TB more effectively 
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among HIV-positive people and to make 
significant public health gains. 
Micronutrients and TB 
Reduced micronutrient intake, and especially 
intake of vitamins and minerals such as vita­
mins A, E, and C, zinc, and selenium, has 
been associated with an impaired immune 
response. There is evidence that at the time 
of diagnosis, patients with active TB have 
depressed blood concentrations of several 
micronutrients, including retinol, vitamins C 
and E, hemoglobin, zinc, iron, and selenium 
compared with healthy controls—in part 
due to the immune system response to infec­
tion. Anemia is commonly found in patients 
with pulmonary TB and appears to be more 
common among TB/HIV co-infected 
patients. Data on the impact of micronu­
trient supplementation on TB outcomes 
are limited. Studies suggest, however, that 
daily supplementation may have an added 
benefit among those who have deficiencies, 
especially during early months of anti-TB 
therapy. Additional research is warranted 
on the impact of multiple micronutrient 
supplements on TB-associated outcomes in 
settings where predominantly cereal-based 
local diets are unlikely to provide adequate 
micronutrient content due to low bioavail­
ability and high fiber content. 
Program experience 
Food assistance is a potentially influen­
tial means for increasing adherence to TB 
treatment, reducing the costs to patients 
of staying in treatment, and for improving 
nutritional status. Food assistance may 
influence early case detection (encouraging 
patients to come sooner for diagnosis 
and treatment), and promote completion 
of the full course of treatment. Both are 
important to decrease TB transmission. 
Although most evidence of the impact of 
food support on TB patients’ nutritional 
status, quality of life, treatment adherence, 
and outcome is anecdotal, there is reason to 
believe that such support will provide direct 
benefits to adults and children infected with 
TB both during and following drug therapy. 
However, the cost to programs of providing 
food support may be considerable. Other 
low-cost interventions, such as periodic 
nutritional assessment, counseling on diet, 
nutritional management of symptoms and 
drug side-effects, may help TB patient 
maintain or increase their food intake and 
adhere to TB treatment. But again, program 
and/or research evidence is limited. 
Research priorities 
Many areas require further investigation to 
improve our understanding and manage­
ment of malnutrition in TB and TB/HIV 
co-infection. Of particular priority are 
studies of the most effective approaches for 
treating malnutrition and improving overall 
nutritional status and muscle mass in TB 
and TB/HIV co-infected adults and chil­
dren during and after TB treatment—taking 
into consideration local diets and food 
availability. Successful and varied models 
for integrating nutritional support into both 
TB and HIV/TB programs, and data on the 
cost-effectiveness of integrated nutritional 
support, are also needed. 
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Introduction
 
The purpose of this paper is to review the 
scientific literature on the role of nutrition 
in Tuberculosis (TB) disease, summarize key 
findings and knowledge gaps, and investi­
gate related programmatic experience. This 
review is intended to guide nutritionists and 
others working in TB control programs, with 
an aim to improve the nutritional manage­
ment of those with active TB disease. A 
focus on nutrition is especially important 
where TB programs are increasing in scale 
to maximize TB diagnosis and treatment. 
Studies included in this review were identi­
fied through a Medline search strategy, using 
the search words tuberculosis and nutrition; 
tuberculosis and HIV; tuberculosis and 
wasting or weight loss; and tuberculosis 
and vitamins, minerals, or micronutrients. 
Additional searches included TB and weight 
or body composition; and TB and protein. 
Abstracts of more than 2,000 citations were 
reviewed, with a focus on published studies 
carried out in Africa and other settings 
where malnutrition is endemic. In addition, 
websites for government and international 
agencies, such as the United States Agency 
for International Development (USAID), 
the World Health Organization (WHO), the 
World Food Programme, and U.S. Centers 
for Disease Control and Prevention (CDC) 
were searched for recommendations and 
nutrition programs. 
I. Tuberculosis 
TB is one of the top ten causes of illness, 
death, and disability worldwide and is the 
leading cause of death from a curable infec­
tious disease.4,5 It is estimated that approxi­
mately one-third of the world’s population 
is infected with Mycobacterium tuberculosis 
(hereafter called latent TB), with 8.8 million 
new cases during 2005 alone.6,9 Considering 
current trends, the annual number of new 
active TB cases is expected to increase to 
9-10 million in the year 2010.4 Smear-posi­
tive TB, the most infectious form of the 
disease, accounts for about 46% of these 
new cases.6,8 Worldwide, about 10% of 
those with latent TB are expected to develop 
active TB disease.6,9 
Epidemiology 
More than 80% of TB patients live in Asia 
and sub-Saharan Africa, considered by 
WHO to be “high burden countries.” Sub-
Saharan Africa has the highest incidence 
of the disease.6,9,10 India, China, Indonesia, 
Bangladesh, and Pakistan together account 
for more than half of the global estimate 
of active TB, as shown in Figures 1-3.6,11 
Population increases in South Asia and 
central Africa alone will account for ~75% 
of new cases of active TB in the next ten 
years.4 For the most part, active TB cases 
have steadily declined in western and central 
Europe, North and South America, and 
in the Middle East, but are increasing in 
sub-Saharan Africa and the former Soviet 
Union.9,10 HIV/AIDS is responsible for 
most of the recent increase in incidence 
in sub-Saharan Africa.6,8 Co-infection with 
HIV greatly increases the lifetime risk that 
latent TB will develop into active disease. 
Approximately 1.6 million people died from 
TB in 2005.6 Deaths from active TB are 
expected to increase to five million a year by 
2050. The main reasons for this increase in 
number of  deaths have been suggested:4,10 
 Increasing populations in countries 
where TB is highly prevalent 
 Increasing poverty 
 The spread of  HIV/AIDS 
 Weak health systems and TB program 
management 
 Insecure funding 
 TB drug resistance 
The relationship between poverty and active 
TB is well established in both developed and 
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developing countries. Most cases of active 
TB (5-6 million annually) occur during the 
economically productive years of people's 
lives (19-49 years),11 compromising earning 
capacity. Poverty is also an underlying risk 
factor for TB. 
Other risk factors include HIV-infec­
tion, sharing a home with someone 
who has active TB, exposure to smoke 
from domestic stoves and cigarettes, 
poorly controlled diabetes, vitamin D 
deficiency, malnutrition, chemotherapy, 
function.4,11,14-16and impaired immune 
HIV is currently the single biggest risk factor 
for development of  active TB disease. 
The collapse of health infrastructure in 
countries experiencing economic crisis or 
civil unrest increases the global burden of 
active TB.10,12 Poorly funded or organized 
TB control programs may not be able to 
offer the full course of treatment, possibly 
resulting in drug resistance. The emergence 
of multi-drug resistant (MDR) and exten­
sively drug resistant (XDR) TB poses a great 
public health threat, particularly in countries 
with high HIV prevalence. 
Pathophysiology 
Mycobacterium tuberculosis (latent TB) from an 
individual with active TB is spread through 
airborne droplets dispersed via coughing, 
sneezing, singing, or talking. These particles 
are very small and can remain airborne for 
minutes to hours.11 TB infection occurs 
when the droplets are inhaled and lodge in 
passageways in the lungs. The bacterium 
is then taken up by macrophages, a type 
of white blood cell that ingests foreign 
substances, beginning a chain of responses 
that result in either containment of the 
infection or development of active disease.11 
A healthy immune system is very effective 
in containing TB but is not able to eradicate 
it,13 because TB bacilli continue to exist in 
the macrophages. 
Following TB exposure, healthy individuals 
mount a cell-mediated immune response 
involving T-cells, macrophages, and cyto­
kines.13 The infection is usually controlled 
and active disease does not develop unless 
the immune function is weakened.11,14-16 A 
positive tuberculin skin test indicates that 
there has been TB exposure and the body has 
developed cell-mediated immunity against 
TB.11 Active TB disease can be caused by a 
recent infection, activation of latent TB, or 
a relapse following earlier treatment.5,10 
In addition to the risk factors mentioned 
above, there is some evidence to suggest 
that genetic factors may play a role in both 
the susceptibility to infection and the devel­
opment of active TB.17 Research in the 
Gambia and South Africa among families 
containing two or more siblings developing 
active TB found two Y chromosomal regions 
linked to susceptibility to active TB, and one 
to the X chromosome. This may partially 
explain the higher incidence of active TB in 
males.18 
The variety of genetic and other risk factors 
for developing active TB underscore the 
complex relationship between the host 
immune system and the TB bacillus in deter­
mining the outcome of  TB infection.19 
Clinical presentation 
Diagnosis 
Bacteriology remains the recommended 
method for diagnosing active TB, first 
through sputum smear microscopy and then 
culture testing.6,10 Culturing TB bacteria is 
expensive and results are not immediately 
available.6,11 In countries where the culture 
is not routinely available, sputum smear is 
the primary diagnostic tool for pulmonary 
TB. However, relying on sputum smears to 
diagnose TB has limitations. For example, 
TB smears detect 65-80% of infections 
confirmed by cultures in low HIV preva­
lence areas. HIV-positive individuals with 
culture-confirmed TB are generally less 
likely to have positive smear results than 
those who are HIV-negative, particularly in 
the later stages of  HIV disease.20 
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Active TB disease 
TB bacteria grow in almost any organ 
system but infection occurs most often in 
the mid to lower lung. Symptoms of active 
TB include persistent cough, fever, night 
sweats, weight loss, shortness of breath, 
coughing up blood, and chest pain.11 
Extra-pulmonary TB is found in about 
20% of HIV-negative individuals. It is more 
common in HIV-positive individuals, in 
women, and in young children. Severe forms 
of extra-pulmonary TB include central 
nervous system TB and abdominal TB.11 
In the era before effective TB treatment 
(and also the advent of the HIV epidemic), 
the TB case fatality rate was reported to be 
between 17-29% within the first year of 
diagnosis, and up to 42-55% after five years. 
With anti-TB therapy, fatalities in industrial­
ized countries decreased dramatically so that 
death due to active TB became an unusual 
occurrence.21 
Treatment 
TB treatment goals include: 
 Cure of active TB disease without 
recurrence 
 Prevention of  transmission 
 Prevention of  drug resistance 
 Improved survival 
Standardized short course chemotherapy is 
used for 6-8 months in confirmed smear-
positive cases.6 Treatment with a combina­
tion of drugs and high adherence are neces­
sary to attain a cure. Treatment usually takes 
place in two phases. 
The initial phase of treatment, during which 
active and dormant bacilli are killed using 
daily drug therapy, lasts 2-3 months and 
shortens the duration of infectiousness in 
80-90% of cases. At least three and pref­
erably four antibacterial drugs, including 
isoniazid and rifampin, are used during the 
initial phase. 
The continuation phase usually uses two 
drugs daily or three times a week and lasts 
4-6 months.11 
Directly observed treatment, short-course 
(DOTS) is an important approach to promote 
adherence to treatment.10 This approach has 
proven successful in improving completion 
rates of anti-TB therapy, reducing multi-
drug resistant disease, and preventing disease 
relapse. The strategy requires sputum smear 
microscopy for diagnosis of infectious 
patients, use of a standardized short course 
drug treatment with supervision and patient 
support (a trained observer is present when 
the patient takes each dose of medication), 
a secure drug supply and management 
system, a recording and reporting system, 
and political commitment.22,6 
The Global Plan to Stop TB includes six 
main components, including expanding 
and enhancing high quality DOTS strategy, 
addressing TB/HIV co-infection and multi-
drug resistant TB, strengthening health 
systems, engaging all providers, empowering 
individuals with TB and their communities, 
and promoting research.23 
Worldwide, DOTS is the standard approach, 
with 187 countries implementing the 
strategy in 2005. A total of 26.5 million new 
and relapse cases were treated in DOTS 
strategy programs between 1995 and 2005.6 
On average, the rate of DOTS treatment 
success in 2004 was 77%, with 74% success 
in the African region.6 
TB in children 
Children are usually infected with TB by 
a smear-positive family member or other 
close contact. Therefore, the most effec­
tive means to prevent childhood TB is early 
identification and proper treatment of infec­
tious cases.12 Children may also be infected 
from untreated cow’s milk containing 
Mycobacterium bovis.12 Although children may 
present with active TB at any age, infection 
is most common between the ages of one 
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and four years, most likely due to an under­
developed immune response. 
In Africa, an estimated 10% of new active 
TB cases occur in children.5 This estimate is 
likely to be low because many sick children 
are not brought to health facilities, and there 
is limited diagnostic capacity in many treat­
ment centers.24 Furthermore, since active 
TB in children often affects more than one 
organ system, signs and symptoms are vague, 
making diagnosis difficult. (See Box 1) 
It is estimated that more than 95% of chil­
dren with active TB would have a negative 
sputum smear. Studies in hospital settings 
have found that extra-pulmonary TB is as 
or more common than pulmonary TB and 
missed diagnosis is as common as over­
diagnosis.7,12 Poverty is the strongest risk 
factor for childhood TB infection since it 
is associated with both poor nutrition and 
household overcrowding, resulting in close 
contact with infectious cases. 
The majority of children with latent TB do 
not develop active TB. Immunosuppressive 
factors such as HIV infection, measles, and 
malnutrition are risk factors for develop­
ment of active disease.12 The risk of active 
TB is five times higher in children with 
HIV.7 Progression to active disease is also 
influenced by age. If the child is infected in 
the first two years of life, disease is more 
likely to progress than if infected between 
ages five and ten years. 
Children under five years of age are at 
increased risk of TB meningitis, which can 
present as headache, fever, and altered mental 
status.7 BCG, or bacille Calmette-Guérin, 
is a vaccine used to prevent childhood 
TB meningitis and miliary disease (small 
nodules or lesions resembling millet seeds). 
WHO recommends the use of neonatal 
BCG as a means to prevent TB meningitis.25 
This vaccination does not prevent TB infec­
tion, but prevents the spread of the bacteria 
to extra-pulmonary locations.7 
Box 1. Symptoms of pulmonary tuberculosis in children compared with adults7 
Feature Adults Children 
Symptoms Cough, fever, chest pain, hemoptysis 
(spitting up blood), weight loss 
Lesions Apical, upper lobes of lungs most 
commonly involved 
Peripheral, often middle and lower 
lobes of lungs 
Cavitation* Common Uncommon, seen during infancy 
and adolescence 
Dissemination 
(extra-pulmonary disease) 
Uncommon Common 
Infectivity Patients with smear-positive 
pulmonary TB are infectious 
*Cavities form in the lung tissue when necrosis involves the wall of an airway 
Usually not infectious 
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II. TB/HIV co-infection
 
Epidemiology 
HIV is responsible for the increase in active 
TB cases in sub-Saharan Africa and increases 
the risk of rapid TB disease progression.8,24 
Worldwide, more than 13 million individuals 
are co-infected with HIV and TB, or about 
one-third of the 40 million people currently 
living with HIV. Approximately 70% of 
those co-infected reside in sub-Saharan 
Africa.9 
The incidence of active TB is more than 
eight times higher in HIV-positive than 
HIV-negative Africans.9,26 In Africa, the 
countries with the largest numbers of co­
infected adults are South Africa (2 million) 
and Nigeria (0.9 million).8 Between 30-50% 
of those infected with HIV will develop 
active TB, while up to 75% of those infected 
with TB are HIV-positive.21, 27 
In many individuals infected with HIV, 
development of active TB disease is the first 
sign of AIDS. Active TB often occurs at a 
higher CD4+ lymphocyte count than other 
HIV-related illnesses. TB is a potent factor 
in the progression of HIV disease.28, 29 Both 
diseases accelerate the progress of the other. 
Active TB often decreases the number of 
CD4+ lymphocytes, increases HIV viral 
replication and shortens the lives of HIV-
positive persons.30,21 The case fatality rate 
for HIV-related TB has been estimated to 
be over 50% in developing countries.8 
HIV infection impairs cell-mediated immu­
nity, increasing the risks of TB infection 
and the reactivation of latent TB in adults 
and children.31 When TB infection occurs 
early in the course of HIV disease, before 
the immune system has been compromised, 
its characteristic features are similar to those 
in HIV-negative patients. However, when 
TB occurs among persons with advanced 
immune deficiency, the majority of patients 
(~70%) present with atypical pulmonary 
disease and about 30% present with extra-
pulmonary (or disseminated) TB.31,32 
The clinical context 
Diagnosis 
Although most HIV-positive patients with 
pulmonary TB are sputum smear-positive, 
the occurrence of negative smears is more 
frequent among the co-infected, making 
TB diagnosis difficult in areas with limited 
laboratory support. In those with extra-
pulmonary TB, the disease may be regularly 
missed.31 In children, almost all pulmonary 
TB cases are smear-negative and diagnosis is 
made according to clinical and radiological 
criteria. 
Smear-negative TB has a worse outcome 
than smear-positive disease in HIV-positive 
persons, with a case fatality rate of about 
50% in Africa.26 The high mortality associ­
ated with co-infection and a sputum-nega­
tive smear is most likely caused by missed 
diagnosis and delayed initiation of treat­
ment. Management of opportunistic infec­
tions in TB/HIV patients is challenging in 
many regions due to inadequate capacity to 
make early diagnosis and the lack of proper 
medications.10 
The number of TB deaths in a population 
is an important marker of the severity of 
HIV’s impact.21 Currently less than 10% of 
TB patients in Africa are tested for HIV. 
HIV testing is usually not available in TB 
clinics.26 However, most countries have 
recently begun to implement collaborative 
TB/HIV activities. While 58% of African 
countries have national policies to offer HIV 
testing for TB patients, only 17% provide 
HIV surveillance of TB patients.10 There 
is an urgent need to improve the scaling 
up of TB/HIV collaborative activities 
including coordination between HIV and 
TB programs in Africa. 
Treatment 
Provision of antiretroviral (ARV) drugs 
can reduce TB incidence in HIV-positive 
persons by 70-80%. (Even so, the incidence 
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of TB in this group remains higher than 
among HIV-negative persons.26,33) TB is 
an opportunistic infection that occurs at a 
higher level of immune function than most 
other opportunistic infections. Thus, the 
potential of ARV treatment to prevent TB 
is highest when ARV therapy is started in 
the earlier stages of  immune deficiency.26,33 
Although most HIV-positive patients with 
active TB respond to anti-TB therapeutic 
drug regimens, it is speculated that drug 
absorption may be suboptimal in patients 
with gastrointestinal symptoms—leading 
to reduced effectiveness of treatment.21 
However the evidence is conflicting and 
study sample sizes are small (Box 2). There 
are also interactions between some TB and 
ARV drugs, which are addressed in WHO 
treatment guidelines.26,34 
HIV-TB co-infection in children 
HIV is a major risk factor for childhood 
TB. Children may contract both infections 
from their mothers. The clinical criteria 
used to diagnose active TB are also the 
most frequent signs and symptoms associ­
ated with HIV infection (failure to thrive, 
chronic cough, recurrent fever, lymphade­
nopathy), making correct diagnosis even 
more difficult.2 WHO provides guidelines 
Box 2. Conflicting studies on TB drug absorption in individuals co-infected with HIV 
Author Subjects Findings 
Gurumurthy et al.3 
India 
. 2 subjects HIV-negative with TB 
2. 0 subjects AIDS with diarrhea* 
. 26 subjects AIDS with TB* 
. 0 subjects healthy 
* not on antiretroviral treatment 
TB drug absorption not different in groups 
 and  but a 2-% reduction in TB drug 
absorption in both AIDS groups (2 and ) 
Gurumurthy et al.6 
India 
.  subjects HIV-negative with TB 
2.  subjects advanced AIDS with 
diarrhea 
.  subjects HIV-positive and TB with
 diarrhea 
Compared to group , -% decreased 
TB drug absorption in group 2; 9-% 
decreased TB drug absorption in group  
Choudhri et al. 
Kenya 
.  subjects HIV-positive with TB 
2.  subjects HIV-negative with TB 
No relationship between diarrhea and HIV 
and TB drug absorption 
Taylor et al. 
South Africa 
.  subjects HIV-positive with TB 
2.  subjects HIV-negative with TB 
No differences between groups in 
absorption and no evidence that HIV 
reduced plasma concentrations of TB 
drugs 
TB/HIV co-infection in children 
Palme et al2 studied 517 HIV-positive and HIV-negative Ethiopian children presenting at a TB clinic. None of 
the HIV/TB co-infected children had been diagnosed with HIV prior to the study. On average, the HIV-positive 
children had been brought to medical clinics 5.6 times before TB diagnosis. Among HIV/TB co-infected children 
41% died, compared with 7% of the HIV-negative TB patients. Among both groups, 90% of the deaths occurred 
in the first two months of TB treatment. Age and low weight-for-age were the only variables predicting death in 
the HIV co-infected group. The lowest weight-for-age scores were amongst the youngest children, who also had 
the highest mortality. The authors conclude that although HIV/TB-co-infected children have a six-times higher 
risk of death than HIV-negative children with TB, the majority of the HIV-positive children (58%) completed 
treatment and were considered cured. 
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on the diagnosis and treatment of children 
with TB/HIV co-infection.39 
There have been several studies of the 
impact of TB/HIV co-infection on the clin­
ical presentation and treatment outcomes 
of children in Africa.2,40,41 These studies 
indicate that mortality is higher in those 
with TB/HIV co-infection, that mortality 
tends to be highest in the youngest children, 
that most of the deaths occurred during 
TB treatment, and that malnutrition was a 
strong predictor of  death. 
Food insecurity, poverty, and 
vulnerability to HIV and TB 
Food insecurity and hunger are common 
among populations throughout Africa and 
are caused by a combination of climatic, 
economic, policy, and political factors, and 
exacerbated by the HIV/AIDS epidemic. 
Since most high HIV-prevalence African 
countries rely on agriculture for food security, 
long-term strategies for food security and 
Disease profile of poverty – Uganda
	
Hospital discharge records from 1992 to 2002 were 
used to describe disease patterns in northern Uganda 
where the population was debilitated by war, internal 
conflict, and epidemics. About 70% of the popula­
tion in the region was internally displaced and living in 
protected camps. During this time period yearly admis­
sions doubled, with the pediatric ward accounting for 
most of the increase. Young children (<4 years) and 
women accounted for 79.5% of all admissions. The 
admissions due to malnutrition peaked at the height of 
civil conflict. The largest number of “bed-days” was 
for patients with active TB (accounting for 20.8% of all 
bed-days), though there was a sharp decline after initia­
tion of DOTS in 2001. HIV/AIDS and TB were the 
leading causes of death in persons aged 15-54 years. The 
authors conclude that long-term war and population 
displacement—with collapse of social structures and 
health systems—result in food shortages, social ineq­
uities, and humanitarian crises. These increase the risk 
of HIV, TB, emerging infections, and malnutrition—all 
contributing to the “disease profile of  poverty.”3 
poverty reduction are challenged, with up 
to 25% of the labor force infected in some 
countries.42 As the epidemic progresses, 
human capital is depleted, agricultural 
resources may be diverted, and farm and 
non-farm income can be lost, affecting 
overall agricultural production—resulting in 
lack of  food and lack of  access to food.43 
Traditionally the victims of famine are largely 
the young and the elderly. HIV/AIDS alters 
this picture to include productive adults 
among those affected by food shortages. 
The resurgence of TB in conjunction with 
the HIV/AIDS epidemic in Africa has had 
a multifaceted impact on the economic and 
social fabrics of  society. 
In order to develop strategies to manage TB 
and HIV better it is important to consider 
factors that affect vulnerability to infection 
and progression of disease. Vulnerability is 
defined as the individual and community 
factors that lead to variability in the impact 
of disease including capabilities to antici­
pate, resist, cope with, and recover from the 
event or illness.24 Individual, household and 
community, and environmental vulnerabili­
ties are summarized in Box 3. 
For more information on nutrition and 
HIV, readers are referred to the papers 
produced by the World Health Organization 
Consultation on Nutrition and HIV/AIDS in 
Africa: Evidence, lessons and recommendations for 
45,46action.
Since there is some evidence in areas of Africa 
that TB stigma and other beliefs may delay 
seeking medical treatment or interfere with 
completion of treatment47, it is important to 
consider these—especially if the individual 
has TB/HIV co-infection.48 Unfortunately, 
there is little published evidence to docu­
ment appropriate interventions to address 
TB and HIV stigma, and additional study 
is needed to fully understand and addressed 
stigma in programs.4 
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Box 3. Vulnerability factors related to progression of disease (Adapted from 2) 
Individual Household/community Environment/institution 
Age 
Sex 
Nutritional status 
Immunity 
Genetics 
Interactions with other diseases 
(such as HIV, diabetes) 
Behavior 
Poverty 
Education 
Knowledge 
Diet 
Livelihood 
Socioeconomic status 
Migration 
Access to treatment 
Geography/physical terrain 
Availability of health services 
Quality of health care 
Availability of appropriate 
treatment 
Emergence of drug resistance 
Development of infrastructure/ 
other services 
Public policy 
Box 4 compares some of the individual conditions that affect vulnerability for TB and HIV 

Box 4. Biological and disease-related vulnerability factors (Adapted from 44) 
Vulnerability 
factor 
Tuberculosis HIV/AIDS 
Age Affects <  yr olds and adults Primarily affects young adults 
Sex Children: males=females 
Adults: males>females 
Adolescents/young adults: females > males 
Adults: males = females 
Genetic influence Ethnic traits 
Vitamin D genes 
Chemokine receptors 
HIV sub-type, clades 
Disease vulnerability 
interactions 
Co-infection with HIV increases 
disease progression 
Sexually transmitted diseases increase 
infectiousness 
Nutritional status May affect incidence, progression, 
and treatment outcome 
May affect incidence, progression, and treatment 
outcome 
Tuberculosis Increases the rate of HIV disease progression 
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III. Malnutrition, immunity, and TB
 
Malnutrition and immunity 
Nutritional status is one of the most impor­
tant determinants of resistance to infection. 
It is well established that nutritional defi­
ciency is associated with impaired immune 
functions.30 While malnutrition limits cell 
mediated immunity and increases suscep­
tibility to infection, infection can lead to 
nutritional stress and weight loss, thereby 
weakening immune function and nutritional 
status.50 
Generalized malnutrition manifests itself 
as low weight-for-height (thinness), and in 
children it is sometimes measured as low 
weight-for-age (underweight) or low height-
for-age (stunting). These conditions, which 
often co-exist with micronutrient deficien­
cies, are often referred to as protein-energy 
malnutrition (PEM) or simply as clinical 
malnutrition. Generalized malnutrition can 
cause significant impairment of several 
important mechanisms of immune protec­
tion, including cell-mediated immunity, 
phagocytic function, antibody concentra­
tion, and cytokine production. 
Malnutrition and TB 
It has long been known that there is an 
association between TB and malnutrition. 
Malnutrition enhances the development of 
active TB, and active TB makes malnutrition 
worse.51,52 It has been suggested that general­
ized malnutrition—by reducing the expres­
sion of gamma interferon, tumor necrosis 
factor alpha, and other mycobactericidal 
substances—may selectively compromise 
portions of the cell-mediated response that 
are important for containing and restricting 
TB.30 
Unfortunately, very few studies have been 
designed to examine the relationship 
between nutrition and the incidence of TB 
or its severity. It is very difficult to deter­
mine accurately what the nutritional status 
of individuals with active TB was before the 
onset of the disease, making it impossible 
to determine whether malnutrition led to 
development of active TB or active TB led 
to malnutrition.1 Furthermore, randomized 
trials—the gold-standard in evidenced-
based medicine—can be difficult to carry 
out in food insecure regions due to ethical 
considerations. 
Several studies report that patients with 
active TB are more likely to be very 
thin (wasted) or have a lower body mass 
index (BMI=wt(kg)/ht(m2)) than healthy 
controls.51,53,54 World Health Organization 
classifications for nutritional status based 
on BMI are shown in Box 5. During the 
wasting process, there is usually a loss of 
both fat and lean (muscle) tissue, with loss 
persisting for several months after the initia­
tion of  anti-TB therapy.55 
For example, in a cross-sectional study, Paton 
and Ng compared the body composition of 
recently diagnosed and wasted TB patients 
to individuals without TB. They found that, 
on average, the body composition difference 
between groups was almost equally distrib­
uted between fat mass and lean body mass 
(6.4kg, 6.0kg respectively) compartments. 
Interestingly, they also found that depletion 
of lean tissue occurred mainly in the limbs, 
while the reduction of fat mass was mainly 
found in the trunk.56 
The wasting commonly found in patients 
with active TB is most likely the result of a 
combination of factors, including decreased 
appetite and food intake, and increased losses 
and altered metabolism associated with the 
inflammatory and immune response.54 
Effects of TB on nutritional status 
During active TB, catabolic processes that 
cause wasting usually begin before the 
patient is diagnosed; therefore more is 
known about nutritional status at the time 
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Box 5. International classification of adult under-
weight, overweight, and obesity according to BMIof diagnosis than of the wasting process 
per se.52 As with HIV infection, at the time 
of diagnosis the metabolic rate or resting 
energy expenditure is increased, resulting 
in increased energy needs to meet the basic 
demands for body function. At the same 
time, energy intakes are likely to decline as 
a result of illness-associated anorexia.57 This 
combination of conditions results in weight 
loss with eventual wasting if energy intakes 
are not increased or energy expenditures 
decreased. Utilization of amino aids and 
protein synthesis may be inhibited due to the 
presence of  pro-inflammatory cytokines. 
Several nutritional parameters are worse 
among newly diagnosed TB patients 
compared to healthy controls: 
	 In a study of patients with active TB 
in the United Kingdom, BMI, muscle 
mass, and subcutaneous fat stores were 
13%, 13%, and 20% lower, respec­
tively, in those with TB compared with 
healthy age-, sex-, and ethnic-matched 
controls.58 
	 Similarly, in a study conducted in 
Malawi, these same parameters were 
20% (BMI), 35% (muscle mass), and 
19% (subcutaneous fat) less in subjects 
with active TB, with a larger decrease 
in muscle mass than among the United 
Kingdom patients.53 
	 In Indonesia, the mean BMI of patients 
with active TB recently admitted for 
treatment was 20% lower than in 
controls (BMI of 18.5 ± 3.2 vs. 21.9 ± 
2.8 in male, 17.8 ± 3.1 vs. 21.9 ±3.5 in 
female patients vs. controls respectively, 
p<0.01). 66% of patients had a BMI 
<18.5 (6 times more frequent than in 
controls). In addition, weight, skin-fold 
thicknesses, mid-upper arm circumfer­
ence (MUAC), fat mass, and fat free 
mass were all significantly lower in those 
with active TB.15 
Classification BMI (kg/m
2)
Principal cut-off points 
Underweight <.0 
Severe thinness <6.00 
Moderate thinness 6.00–6.99 
Mild thinness .00–.9 
Normal range .0–2.99 
Overweight ≥25.00 
Pre-obese 2.00–29.99 
Obese ≥30.00 
Obese class I 0.00–-99 
Obese class II .00–9.99 
Obese class III ≥40.00 
Source: Adapted from WHO, 1995; WHO, 2000 and WHO, 2004. 
	 In an Ethiopian study of 155 patients 
with active TB (81 HIV-negative and 74 
TB/HIV co-infected) and 31 controls, 
BMI <18.5 was common (65.4% of TB 
patients, 71.6% of TB/HIV co-infected), 
and severe malnutrition (BMI<16) was 
more common in those co-infected.59 
	 Wasting is associated with increased 
mortality in those with active TB. In 
a study of 1,181 newly diagnosed TB 
patients in rural Malawi, 57% were 
underweight (BMI <18.5), including 
21% with BMI<16. A BMI <17.0, indi­
cating moderate to severe malnutrition, 
was associated with a two-fold increased 
risk of early death.60 Advanced lung 
disease was associated with low BMI and 
fat mass in another Malawian study.51 
Effect of nutritional status on TB 
Cell mediated immunity is the most 
important defense against TB. An already 
malnourished individual is more likely to 
become infected with TB, and latent infec-
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tion is more likely to become active TB 
when the cell mediated immunity response 
is impaired. In fact, among individuals with 
latent TB, the occurrence of malnutrition 
may be an important trigger for active TB 
development.1 
Most data on the relationship between the 
nutritional status and the development of 
active TB come from studies carried out in 
the 1950s to 1970s in developed countries. 
One longitudinal study of participants in a 
BCG vaccine trial conducted in the United 
States found the incidence of active TB 
was 2.2 times higher in children with low 
subcutaneous fat stores (skin-fold thick­
nesses between 0 and 4mm) compared with 
those with 10mm subcutaneous fat.61 In a 
large study conducted in Norway, the inci­
dence of smear-positive and smear-negative 
TB declined significantly with increasing 
BMI in all age groups. New TB diagnosis 
was 5 times higher in the lowest BMI group 
compared with the highest BMI group.62 
Nutritional status changes during 
TB treatment 
Body weight is made up of fat free mass 
(muscle) and fat mass. Adequate muscle 
is generally related to physical function. 
Nutrient partitioning is defined as the 
relative distribution of weight loss or gain 
between fat and fat free (muscle/protein) 
stores. During drug treatment of active 
TB without supplementary nutrition,
nutritional status usually improves. This is 
most likely for a variety of reasons including 
improved appetite and food intake, reduced 
energy/nutrient demands, and improved 
metabolic efficiency. Most improvements, 
however, are limited to increases in fat 
mass.52 
For example, Schwenk et al. investigated the 
changes in fat mass and protein mass in 40 
TB patients in England receiving standard 
TB treatment. The patients reported loss 
of 10.1±6.8% of body weight in the five 
months before diagnosis. After six months 
of treatment, the patients had gained 9.5 ±
8.9% body weight, mainly due to gain in fat 
mass with no significant change in protein 
mass. The authors suggest that clinical 
recovery from TB does not guarantee protein 
mass restoration, even though weight gain is 
significant.63 This finding may support the 
idea that protein metabolism continues to 
be altered even during treatment, and that 
clinical and functional recovery from TB 
lags behind microbial cure. Alternately, diet 
during treatment may have been inadequate 
in relationship to increased requirements 
during treatment and recovery, thereby 
limiting development of  lean body mass. 
Although nutritional support during TB 
treatment is often recommended, there are 
few published studies on the effectiveness 
of such support. Three studies are summa­
rized below. However, only the first one was 
a randomized trial: 
	 Paton et al. conducted a nutritional 
support study in Singapore that 
randomized 36 patients who recently 
started anti-TB drug treatment to a 
high energy-protein supplement (600­
900kcal/d, 25-37.5gm protein/d) for 
six weeks compared with a control TB 
group not receiving the supplement. All 
participants were given nutrition coun­
seling to correct imbalances noted in 
reported dietary intake. Food intake was 
assessed via recall, and was reported to 
not differ between groups at baseline. 
At six weeks, the subjects in the nutri­
tion supplement group had a significant 
increase in body weight compared with 
controls (2.6 ± 1.8 vs. 0.8 ± 0.9kg, 
p=0.001), and in lean mass (1.2 ± 0.9 
vs. 0.04 ± 1.3kg, p=0.006). Fat mass 
increased in both groups. In addition, 
there was a significant increase in grip 
strength in the supplement group. At 
12 weeks, the supplement group had a 
greater increase in body weight than the 
control group, but the difference was 
no longer statistically significant by 24 
weeks (4.4 ± 2.7 vs. 2.7 ± 2.5, p=0.07). 
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However, it is important to note that 
the sample size may have been too small 
to detect a statistical difference after 
supplementation ceased and the 1.7kg 
difference may be of clinical importance. 
Nearly half of the early weight gain in 
the supplemented group was lean tissue, 
suggesting that TB patients are able to 
build muscle mass during recovery. The 
authors suggest that accelerating the 
recovery of lean tissue through nutrition 
support may help restore physical func­
tioning earlier, shortening the convales­
cent period and allowing earlier return 
to productive work. They also suggest 
that since poor nutrition in TB patients 
is associated with mortality, a more rapid 
reversal of malnutrition may help to 
improve TB patients’ survival.54 
	 In an early nutrition study of 30 TB 
patients in England followed for one 
year after anti-TB treatment, drug treat­
ment was associated with progressive 
nutritional recovery of BMI, fat stores, 
and iron status. At 12 months however, 
MUAC and serum albumin remained 
low, suggesting that repletion of muscle 
mass may take longer than 12 months.58 
Alternately, diet during convalescence 
may have been inadequate to support 
repletion. 
	 In a study of 174 smear-positive pulmo­
nary TB patients in Tanzania followed 
for one year, most patients lost weight 
after discharge from hospital treatment. 
At 12 months 32% of males and 19% 
of females considered cured of their 
TB continued to have a BMI <18.5, 
indicating malnutrition continued after 
TB treatment.64 
Nutritional status and TB relapse 
Nutritional status may have an effect on 
relapse of active TB. To investigate the rela­
tionship between change in weight during 
anti-TB drug therapy and active disease 
relapse, Khan et al. monitored 857 HIV-
negative patients with active TB during, 
and two years after, their drug treatment. 
Relapse risk was increased amongst those 
who were ≤90% of ideal body weight 
(19.1% vs. 4.8%, p<0.001; RR 3.99; 95% 
CI 2.3-6.76, p<0.001) or had a BMI ≤18.5 
(19.5% vs. 5.8%, p<0.001; RR 3.92; 95% 
CI 2.22-6.91, p<0.001) at the time of diag­
nosis. Using multivariate logistic regression, 
in those who were underweight at diagnosis, 
weight gain of less than 5% between diag­
nosis and completion of the initiation phase 
of therapy was significantly associated with 
relapse (OR 2.4, p=0.03).65 Additional study 
is needed to determine whether nutritional 
support to underweight patients with active 
disease prevents relapse following anti-TB 
treatment. 
Serum albumin levels and TB 
Many studies have reported low concentra­
tions of serum albumin (<35g/L), an indi­
cator of protein status, at the time of active 
TB diagnosis.66 However, cytokines present 
during the acute phase response to active 
infection down-regulate serum albumin 
levels. Low albumin in patients with active 
infection is therefore difficult to interpret 
without another laboratory measure of an 
acute phase process. Low levels of albumin 
may reflect the presence of inflammation 
rather than a protein deficient state.67 Taking 
this important limitation into account, 
studies reporting the correlation between 
serum albumin levels and active TB are 
summarized below. 
	 Researchers in Ethiopia reported that 
serum albumin was significantly lower 
in TB patients compared to healthy 
controls (29.7 ± 7.7 vs. 42.2 ± 2.9, 
p<0.001).68 
	 Likewise in Malawi, researchers found 
that serum albumin was low in newly 
diagnosed TB patients compared with 
healthy controls (31.4 ± 8.1 vs. 39.9 
± 6.3, p<0.001). After two months of 
anti-TB treatment, mean serum albumin 
increased significantly to the level of 
the healthy controls at 39.6 ± 5.8, 
(p<0.0001).69 
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	 In South Africa, median serum albumin 
in newly diagnosed TB patients before 
isoniazid (INH) treatment was initiated 
was low (median 30.5 g/L, IQR 27.5­
33.5). After seven days of INH treat­
ment, albumin concentrations increased 
significantly (median 32g/L, p<0.001).70 
Malnutrition and TB/HIV co-infection in 
adults 
TB and HIV infections are both independ­
ently associated with malnutrition. TB/HIV 
co-infection poses an additional metabolic, 
physical, and nutritional burden, resulting 
in potential further increase in energy 
expenditure, malabsorption, micronutrient 
deficiency, and increased production of 
pro-inflammatory cytokines resulting in 
breakdown of body lipids and proteins.71,66 
Co-infection may lead to poor appetite with 
decreased nutrient intake, which may interact 
with the altered metabolism associated with 
both infections as part of the immune and 
inflammatory responses.72 The combination 
of TB/HIV co-infection and malnutrition 
has been termed “triple trouble.”66 Studies 
on differences in nutritional status (BMI) 
among HIV-positive and HIV-negative TB 
patients are summarized in Annex 1. 
To investigate the impact of HIV on nutri­
tional status in patients with active TB, 
Niyongabo et al. compared the nutritional 
status of HIV-positive and HIV-negative 
hospitalized TB patients in Burundi in a 
cross-sectional study. Mean anthropometric 
measures were all significantly less in the 
TB/HIV co-infected compared with the 
HIV-negative TB patients (BMI 15.6 ± 3.4 
vs. 18.5 ± 2.5 kg/m2, arm fat area 17.9 ± 2.3 
vs. 19.7 ± 3.2 cm2, arm muscle area 29.3 ± 
8.5 vs. 37.5 ± 10.3 cm2 respectively, p=0.01), 
indicating lower body weight, fat mass, 
and fat free mass in the HIV co-infected 
cases. Anthropometric indices tended to 
underestimate the severity of malnutrition 
in comparison to bioelectrical impedance 
measures of body composition. Co-infected 
patients also had significantly lower mean 
serum albumin compared with HIV-nega­
tive TB patients (18.9 ± 6.1 vs. 28.9 ± 6.9 
g/L respectively, p=0.01) and lower pre-
albumin (0.08 ± 0.05 vs. 0.13 ± 0.06 g/L 
respectively, p=0.01). The authors suggest 
that the TB/HIV co-infected patients may 
have either more severe malnutrition or 
increased inflammation, and that these 
proteins may have a useful prognostic value 
in HIV-positive TB patients.71 
	 In Tanzania, Villamor et al. conducted 
a large cross-sectional study to evaluate 
the role of HIV in wasting among 
2,231 patients with active TB, and to 
identify correlates of wasting including 
socioeconomic factors. MUAC and arm 
muscle area were significantly lower in 
TB/HIV co-infected patients compared 
to HIV-negative TB patients, but there 
was no difference between groups in 
BMI.67 Mean serum albumin concentra­
tions were significantly lower in the TB/ 
HIV co-infected patients (28.0 ± 10 in 
co-infected vs. 32.0 ± 11 in active TB 
only patients; p=0.004). Interestingly, 
the Tanzanian TB/HIV co-infected 
patients had higher BMI than the 
Burundi patients described above. The 
mean BMI of the TB/HIV co-infected 
men in the Tanzanian study (19.0 ± 2.4 
in HIV-positive vs. 18.9 ± 2.2 in HIV-
negative) was about 21% higher than in 
the Burundi study. Additionally, wasting 
was positively associated with the 
severity of TB, while BMI, MUAC, and 
arm skin-fold thicknesses were posi­
tively associated with socioeconomic 
status and Karnofsky score (a higher 
score indicating increased physical func­
tioning) and negatively associated with 
bacillary density.67 
	 In another study carried out in Tanzania, 
Venkatesh et al. examined predictors of 
incident active TB in 1,078 HIV-positive 
women attending antenatal clinics and 
found that 8.7% developed active TB 
during the follow-up period. Baseline 
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CD4+ counts were lower and plasma Malnutrition and TB/HIV co-infection in
viral load higher in those who devel­ children 
 
oped TB. Women with CD4+ counts 
<200cells/mm3 were at the greatest risk 
of developing TB, as were those with 
baseline MUAC <22cm. Death rates 
were higher in HIV co-infected women 
(63% in TB/HIV co-infected vs. 23% in 
HIV-positive only).73 
To understand protein metabolism better 
in TB/HIV co-infected patients, Paton 
et al. conducted a small metabolic study 
in Singapore of ten patients with HIV 
alone, ten patients with active TB alone, 
eight TB/HIV co-infected patients, and 
compared them with 11 healthy controls. 
They found that patients with only TB 
had lower BMI than patients with only 
HIV and the healthy controls. In both 
TB groups, wasting was characterized by 
Several studies have documented an 
increased risk of malnutrition among TB/ 
HIV co-infected children. No studies of the 
impact of nutritional support among TB/ 
HIV co-infected children were identified. 
In a study of Ethiopian children, 60% 
of the co-infected children aged one 
month to 14 years had weight-for-age 
(WFA) z-scores <-2.00 (i.e., z-scores 
were more two standard deviations 
below the reference median), compared 
with 46% of the HIV-negative and 19% 
of  healthy children.2 
In a study of South African children 
co-infected with HIV at TB diagnosis, 
25% had WFA z-scores <-3.00 and 47% 
had WFA z-scores <-2.00.41 
 
 
overall loss of body fat and lean tissue Another South African study of 250  
in arms and legs, and there was evidence children <15 years old with active TB 
of ongoing inflammation based on reported that underweight (WFA z-score 
elevated erythrocyte sedimentation rate <-2.00) was more common in those co­
and C-reactive protein concentrations. infected with HIV (77%) compared to 
Protein change and degradation was those with TB alone (56%) (OR 2.62; 
lower in the HIV alone group. 95% CI 1.08-6.43). TB/HIV co-infected 
 The rates of protein change, synthesis, 
and degradation were not different 
between the TB alone and the healthy 
control group, but in the TB/HIV co­
infected group the net protein balance 
was close to zero and lower than the 
children were also more likely to have 
severe malnutrition (OR 2.57; 95% CI 
1.02-6.50). The nutritional status of 
all children improved during hospital­
ization, but WFA remained lowest in 
the TB/HIV co-infected children. At 
other groups, perhaps due to the meta­
bolic disturbances associated with a 
discharge from the hospital, 47% of 
the co-infected remained underweight 
secondary infection and more advanced (WFA z-score <-2.00).40 
disease. The authors conclude that their 
findings support the case for providing 
additional nutrition for TB/HIV co­
infected patients during treatment.72 
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Generalized malnutrition, immunity, and TB summary 
	 The above studies highlight the complex relationships between generalized malnutrition and active 
TB but few studies have been carried out to assess the direct benefits of providing nutritional support 
to malnourished TB patients. 
	 Randomized trials are difficult to carry out due to ethical considerations. 
	 Although the evidence is limited, available data suggest that malnutrition affects cell-mediated immu­
nity, which is critical for controlling TB infection, and may increase the risk of active TB disease 
development by six to ten times. 
	 Targeting nutritional support to malnourished populations at high risk for TB could potentially reduce 
the incidence of active TB in these groups, although this has not been directly proven. 
	 It is important to note that mild-to-moderate malnutrition typically affects larger segments of the popu­
lation than severe malnutrition, so prevention efforts most likely will not be successful if they only 
target the severely undernourished. 
	 TB treatment improves nutritional status but treatment alone is probably not sufficient to achieve 
adequate nutrition among patients living in food insecure areas. 
	 Active TB affects protein metabolism and nutritional status through multiple mechanisms and, exam­
ined together, the evidence suggests that adequate nutritional intake during TB care and recovery will 
be needed to fully restore nutritional status during and following TB treatment and microbial cure. 
	 Adults and children co-infected with HIV and TB are at greatest risk of malnutrition, poor treatment 
outcomes, and death. 
	 Efforts to prevent, manage, and treat TB and HIV have been largely separate endeavors, despite the 
overlapping epidemiology. Although progress is being made, improved collaboration between TB and 
HIV/AIDS programs is necessary to control TB more effectively among HIV-positive people and to 
make significant public health gains. 
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IV. Micronutrients and TB
 
Although generalized malnutrition, as 
reviewed above, has been commonly 
described in those with active TB, less is 
known about micronutrient status and the 
TB disease process.66 Vitamins A, C, E, B6 
and folic acid and minerals zinc, copper, 
selenium, and iron all have key roles in 
metabolic pathways, cellular function, and 
immune competence.74 The concentration 
of these may have a role in host defense 
against TB.15 Deficiency of single or 
multiple nutrients can reduce an individual’s 
resistance to any infection.50,74-76 In the era 
before drug management of active TB, 
administering cod liver oil (rich in vitamins 
A and D) was a common therapy to improve 
host defense.66 
Vitamin A and antioxidants 
Reduced micronutrient intake, and espe­
cially intake of vitamin A and antioxidant 
vitamins and minerals such as pro-vitamin 
A carotenoids, vitamins E and C, zinc, 
and selenium, has been associated with an 
impaired immune response.50 Antioxidants 
neutralize free radicals by sacrificing one 
of their own electrons. (Free radicals are 
unbound electrons that react quickly in an 
effort to capture another unbound electron 
and thus gain stability.) TB may induce 
oxidative substances such as reactive oxygen 
species (ROS) derived from free radicals, 
which in turn can promote tissue injury 
and inflammation. ROS are highly toxic 
to all types of cells, but especially to lipids 
(fat cells) causing peroxidation, resulting 
in damage to cell membranes, and are also 
associated with the pathogenesis of lung 
fibrosis and dysfunction in pulmonary 
TB.68,77 Antioxidants scavenge free radicals 
and suppress the actions of ROS, protecting 
the host from tissue inflammation. 
Vitamin A, which is usually assessed using 
serum retinol, also plays important roles 
in lymphocyte proliferation, generation of 
antibody responses, and maintenance of 
mucosal surfaces and epithelial function.50 
Vitamin E protects cell membranes against 
lipid peroxidation and oxidative stress by 
scavenging free radicals and by stabilizing 
cell membranes. In animals, vitamin E is 
mobilized from tissues and diverted to 
the lungs during oxidative stress.77 Zinc 
is essential for DNA synthesis and cell 
differentiation. Zinc deficiency is associated 
with recurrent infections, decreased phago­
cytosis, decreased B and T lymphocyte 
production,78 and depressed macrophage 
activity.79 Selenium is an essential part of 
antioxidative enzymes, such as glutathione 
peroxidase, which protects cells from oxida­
tive damage.59 
It must be noted that blood micronutrient 
status is difficult to assess in the presence 
of infection because biochemical indicators 
of several micronutrients are affected by 
the immune system’s acute phase response. 
Serum ferritin (a measure of iron status) 
and copper are “positive” acute phase reac­
tants that increase when the immune system 
responds to an infection, while albumin, 
retinol, and zinc are “negative” reactants. 
Thus, results of some studies on the rela­
tionship between micronutrient status 
and TB infection may be confounded by 
increased rates of  acute phase response. 
In people with infections, measurement of 
“positive” acute phase reactants, such as 
serum ferritin and copper, may underes­
timate nutrient deficiency, while measure­
ment of negative responders, such as serum 
albumin, retinol, and zinc, may lead to an 
overestimation of underlying deficien­
cies. To give a specific example, during the 
acute phase response to infection, retinol is 
excreted in the urine and the liver’s produc­
tion of retinol-binding protein required to 
mobilize vitamin A from tissue stores is 
also reduced, resulting in low serum retinol 
levels. These levels may lead some reserches 
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to conclude that there is vitamin A defi­
ciency when in fact the low serum value is 
primarily an indicator of the presence or 
severity of disease. Thus, researchers should 
also collect markers of the acute phase 
response—although they frequently do not. 
Studies of micronutrient status and TB 
As expected, there is evidence that at the 
time of diagnosis active TB patients have 
lower blood concentrations of several 
micronutrients including retinol, vitamins C 
and E, hemoglobin, zinc, iron, and selenium 
compared with healthy controls. Studies 
on the relationship between micronutrient 
status and TB are summarized in Annex 2. 
	 The micronutrient status of 41 adult 
Indonesian patients with active pulmo­
nary TB prior to anti-TB treatment was 
compared with an equal number of 
healthy matched controls. The mean 
plasma retinol, hemoglobin, and zinc 
concentrations were significantly lower 
in the TB patients. More TB patients 
were classified as having marginal or 
deficient micronutrient status (33% TB 
patients with retinol <0.70µmol/L vs. 
13% controls, p<0.05; 58% TB patients 
with hemoglobin <12g/L compared 
with 22% controls, p<0.05; 21.1% 
TB patients with zinc <10.7 µmol/L 
vs. 5.1% of controls, p<0.01). More 
than half of all subjects had tocoph­
erol (vitamin E) concentrations below 
normal (11.5 µmol/L), but it was not 
different by group.15 No markers of an 
acute phase response were used in the 
analysis. 
	 In a study of circulating antioxidants 
and a marker of oxidative stress, 
125 Ethiopian patients with active 
TB (before starting drug treatment) 
were compared with Norwegian and 
Ethiopian healthy controls. Karnofsky 
score, a simple scale used to catego­
rize physical ability, was also measured. 
The TB patients had significantly lower 
serum concentrations of vitamins C and 
E compared with controls, while malo­
ndialdehyde concentration, a measure 
of lipid peroxidation and oxidative 
stress, was significantly higher in the TB 
patients.68 A higher malondialdehyde 
concentration was also associated with 
poor Karnofsky physical performance 
scores, indicating increased clinical 
severity.68 These results indicate that the 
TB patients had higher oxidative stress 
and lipid peroxidation but low antioxi­
dant capacity. 
	 In another study of lipid peroxidation 
and antioxidants, 30 newly diagnosed 
and untreated pulmonary TB patients 
from India were compared with healthy 
matched controls. Thiobarbituric acid 
reactive substances (TBARS), a marker 
of lipid peroxidation, was significantly 
increased in the TB patients compared 
with controls, while the plasma levels 
of vitamins C and E were significantly 
decreased.77 
Vitamin A 
As anticipated, because of the acute phase 
response, serum retinol levels are generally 
lower in patients with active TB, particularly 
those who are TB/HIV co-infected, and 
tend to improve with anti-TB therapy. 
	 In a study of vitamin A deficiency in 
Tanzania, serum measurements were 
obtained from patients with pulmonary 
TB upon admission to the hospital and 
after two months of TB treatment and 
compared with blood donor controls. 
At baseline, mean serum vitamin A was 
significantly lower in the TB patients 
than in controls, with TB/HIV co­
infected patients having the lowest 
concentrations (13.1 ± 5.6µg/dl in the 
co-infected vs. 26.6 ±5.4µg/dl in the 
controls). Almost 90% of TB patients 
were classified as vitamin A deficient 
(<20µg/dl), with a higher proportion 
of the TB/HIV co-infected considered 
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vitamin A deficient compared with 
controls (43% vs. 26% respectively, 
p<0.001). After two months of TB treat­
ment, mean vitamin A status improved 
in the HIV-negative TB patients with 
fewer classified as vitamin A deficient, 
but was slightly worse in the co-infected 
patients with a larger proportion defi­
cient. HIV infection was the strongest 
predictor of low vitamin A at baseline 
and at two months.69 
	 The vitamin A status of newly diag­
nosed pulmonary TB patients in India
was compared with a similar number 
of close family contacts without illness 
and healthy normal controls. At the start 
of TB treatment, 81% of the patients 
were considered low in vitamin A (in 
this study defined as a retinol concentra­
tion < 30µg/dl) compared with 24% of 
household contacts and 7% of controls. 
The TB patients’ mean vitamin A (21.2 
µg/dl) was significantly lower than 
household contacts or healthy controls 
(42.2 and 48.1µg/dl, p<0.001). After 
six months of anti-TB treatment, 93% 
of TB patients had improved serum 
vitamin A concentrations, but 32% 
remained abnormally low. The authors 
note that after six months of treatment, 
the mean serum vitamin A concentra­
tion of the TB patients was similar to the 
household contacts and normal control 
group, presumably due to control of the 
acute response to infection rather than 
because of improved vitamin A status.80 
Ascorbic acid (vitamin C) 
In the first half of the twentieth century, 
before drug treatment for active TB was 
available, low vitamin C intake and lower 
plasma vitamin C concentrations were asso­
ciated with increased TB incidence.81 vitamin 
C, together with vitamin E and glutathione, 
are important for pulmonary antioxidant 
defense.82 Since the lung is exposed to 
many oxidizing chemicals during normal 
breathing, an inadequate concentration of 
vitamin C in the lung and blood can lead 
to an imbalance between antioxidants and 
oxidants. In spite of this long-established 
relationship, there are few studies on vitamin 
C status and active TB risk and outcomes. 
No studies in HIV/TB co-infected patients 
were identified. 
	 Researchers in Russia studied 159 
patients with pulmonary TB who smoked 
cigarettes and 20 smokers without TB to 
measure metabolic changes in vitamin C 
and its metabolites. The levels of  serum 
ascorbic acid in the TB patients were 
significantly lower than in the controls. 
The authors suggest that the presence of 
TB lung inflammation leads to decreases 
in serum ascorbic acid levels and that the 
reduced metabolites indicate a slowing 
metabolism of ascorbic acid in this 
population. The authors raise the possi­
bility that use of supplemental vitamin 
C in cigarette-smoking TB patients may 
not be helpful, as it is poorly utilized, 
and that dehydroascorbic acid, another 
form of vitamin C, as a supplement may 
need to be considered.82 
	 Researchers in Finland studied whether 
an intake of vitamin C and foods high 
in vitamin C were related to the inci­
dence of active TB among smokers in 
the Alpha-Tocopherol, Beta-Carotene 
Cancer Prevention study. Median 
dietary intakes were 90 mg/d vitamin C, 
and 183 g/d of fruits, vegetables, and 
berries. There were 167 incident cases 
of active TB between 1985 and 1993. 
Higher vitamin C intakes were not asso­
ciated with reduced risk of active TB 
when consumption of fruits, vegetables, 
and berries was fixed, suggesting that 
compounds in these foods other than 
vitamin C affect susceptibility to active 
TB. In fact, increased intakes of fruits, 
vegetables, and berries low in vitamin C 
content were associated with a reduced 
risk of  TB.81 
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Pyridoxine (vitamin B6 ) 
Shortly after isoniazid (INH) treatment for 
active TB was introduced in 1952, it was 
noted that patients treated with the drug 
developed peripheral neuropathy (symp­
toms include numbness, pain, and burning 
sensation in the feet), a wide-ranging condi­
tion referring to disorders of peripheral 
nerves that branch out from the spinal cord 
to all parts of the body. Pyridoxal phos­
phate (PLP) is a co-enzyme required for the 
synthesis of neurotransmitters. INH inhibits 
the phosphorylation of pyridoxine, which 
results in increased excretion of vitamin 
B6.
70 Therefore, current treatment guide­
lines recommend that patients on INH with 
burning feet symptoms take supplemental 
pyridoxine.12 It should be noted that INH is 
just one of the medications that may be used 
in TB treatment. INH prophylaxis is given 
if an individual has been recently infected 
with TB and the risk for progression to 
active disease is high (for example, in young 
children and in HIV-positive individuals). 
	 Visser et al. measured PLP in newly diag­
nosed active TB patients before and one 
week after initiation of INH therapy 
in Cape Town, South Africa. At study 
entry, only two out of 29 had normal 
plasma PLP (>24.3nmol/L) and all but 
one patient had a significant further 
reduction of PLP concentration one 
week after initiation of INH therapy. 
The authors conclude that most patients 
with newly diagnosed pulmonary TB 
have suboptimal levels of plasma 
PLP when they are diagnosed, which 
worsens with INH treatment, and that 
routine pyridoxine supplementation is 
warranted.70 
Vitamin B6 status in TB/HIV co-infected 
patients has not yet been described. 
Vitamin D 
Susceptibility to TB and severity of 
active TB may be increased by vitamin 
D deficiency.83,84 Humans have two main 
means to obtain vitamin D. Vitamin D 
can be consumed as cholecalciferol (or 
D3) in fish, meat, and vitamin D fortified 
foods, and it can be formed via exposure 
to sunlight, which converts a form of 
cholesterol into pre-vitamin D, which is 
then activated by the liver and kidney.84 
The role of vitamin D in resistance to 
active TB has been known for more than 
100 years, as vitamin D-rich cod liver oil 
and exposure to sunlight were once part 
of regular therapy for TB.19 Vitamin D is 
required for macrophage activation, which is 
essential for keeping TB in the latent phase. 
In addition, vitamin D down-regulates the 
transcription of a substance that is needed 
for the intracellular survival of TB bacillus 
in macrophages, further containing the 
bacilli.84,85 Vitamin D deficiency allows the 
disease to progress to the active form. 
	 More recently, the role of vitamin D in 
the TB disease process re-emerged with 
the increased incidence of active TB in 
the winter months among individuals 
from the Indian subcontinent after 
moving to the United Kingdom. It
was hypothesized that immigrants from 
tropical countries, where latent TB is 
common, had a marked decrease in their 
serum vitamin D levels when they lived 
in cold and cloudy England, with consid­
erably less opportunity for exposure to 
sunshine.19 Poverty is not considered to 
be a factor as these immigrant commu­
nities are generally prosperous.14 To test
this hypothesis among immigrants in 
London, the plasma vitamin D3 levels of 
210 patients diagnosed with active TB 
were regularly measured. Of all subjects, 
76% were deficient in vitamin D (<22 
nmol/L) and 56% had undetectable
concentrations.85 
	 Another study conducted among 
Gujarati Indians living in London, 
England, found a high prevalence of 
vitamin D3 deficiency, with the lowest 
concentrations found in those with 
active TB. The odds ratio of active TB 
increased with decreasing vitamin D3 
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concentrations (OR 2.9; 95% CI1.3-6.5 
in those with vitamin D3 <10 nmol/L; 
OR 9.9; 95% CI1.3-76.2 in those with 
vitamin D3 undetectable, p<0.01).
14 
The authors conclude that low dietary 
intake of vitamin D combined with lack 
of exposure to sunshine are the main 
factors in vitamin D deficiency that 
contribute to the acquired susceptibility 
to active TB in this population.14 
The combination of a specific genotype 
with vitamin D deficiency is suggested to 
strongly predispose a person with latent TB 
to active disease.19 Resistance to infection 
may be determined genetically through the 
ability of vitamin D to activate macrophages 
to consume and destroy the TB bacilli. 
Effects of vitamin D are mainly determined 
through a vitamin D receptor, which has 
common polymorphisms (minute variations 
of a trait that occur in human DNA) that 
influence vitamin D receptor activity. These 
polymorphisms are potentially the means of 
genetic susceptibility to active TB.86 
	 In a Peruvian study of pulmonary TB 
patients living in a community with 
high TB incidence, certain vitamin D 
receptor polymorphisms were associ­
ated with significantly faster resolution 
of pulmonary TB with DOTS strategy 
treatment, while another polymorphism 
was associated with a more aggressive 
disease process and a slower response 
to treatment. The authors also note 
that rifampin and isoniazid treatments 
may alter vitamin D metabolism and 
influence the polymorphisms during 
treatment as well. They suggest that 
vitamin D supplementation may be 
beneficial and that further study on this 
is warranted.83 
Vitamin D status in HIV/TB co-infected 
patients has not yet been described. 
Trace elements 
Trace element blood concentrations 
in persons with active TB are not well 
documented. 
	 A study was conducted examining 
serum concentrations of zinc, iron, 
copper, and selenium in 155 patients 
with active TB in Ethiopia before and 
after anti-TB drug treatment, compared 
with 31 healthy control subjects. At 
baseline before drug treatment, mean 
serum zinc, iron, and selenium in TB 
patients were lower than in controls, 
and a higher proportion was considered 
to be deficient (zinc deficient 47.1% in 
TB patients vs. 25.8% in controls, iron 
deficient 14.8% in TB patients vs. 3.2% 
in controls, selenium deficient 35.5% 
in TB patients vs. 22.6% in controls). 
After two months of anti-TB drug 
treatment, the mean zinc concentration 
increased significantly in TB patients 
(87.3 ± 26.8 before vs. 118.3 ± 59.6 
µg/dl after treatment, p<0.05), but not 
in HIV-co-infected subjects, nor for the 
other trace elements measured. The 
low serum zinc at baseline was prob­
ably due to redistribution of zinc from 
serum to other tissues or an alteration in 
transport proteins, both associated with 
an acute phase response.59 Since serum 
concentrations of iron, zinc, and copper 
are altered with infection and an acute 
phase response, a limitation of this 
study is that the presence of an acute 
phase process was not measured. 
Iron and anemia 
Anemia is common in patients with 
pulmonary TB, and appears to be more 
common among TB/HIV co-infected 
patients. Proposed reasons for this include 
increased blood loss from hemoptysis 
(blood in sputum for TB patients), bone 
marrow involvement (decreased red blood 
cell production), inadequate intake (poor 
appetite and food intake) resulting in poor 
micronutrient status, and anemia of chronic 
inflammation (decreased circulating iron 
with increased storage iron, making iron less 
available to microbes).87, 88 
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	 In a study of micronutrient status and 
anemia conducted in Malawi among 
500 newly diagnosed pulmonary TB 
patients (including 370 co-infected with 
HIV), the prevalence of anemia was 
high and more common in those HIV 
co-infected (76.9% in TB patients and 
88.4% in co-infected patients, p=0.002). 
Micronutrient deficiencies were common 
in all patients, with 59% deficient in 
vitamin A, 12% deficient in vitamin E, 
80% deficient in zinc, and 88% deficient 
in selenium. Decreased concentrations 
of retinol, carotenoids, and selenium 
were associated with increasing degree 
of anemia. The authors suggest that 
selenium deficiency may contribute to 
anemia via increased oxidative stress.87 
In contrast, iron overload occurs in approxi­
mately 10% of some rural African popula­
tions and is attributed to high dietary iron 
intake from consumption of traditional 
fermented beverages. Iron loading may 
enhance the growth of mycobacterium tubercu-
losis by impairing macrophage suppression 
of  invading microorganisms. 
	 In a study of 98 pulmonary TB patients 
and 98 control subjects in Zimbabwe, 
estimates were made of lifetime tradi­
tional beer consumption. Increased 
dietary iron was defined as an estimated 
lifetime consumption of >1000L of 
traditional beer. Iron indices were 
measured until nine months after the 
start of anti-TB drug therapy. At the 
beginning of therapy, the mean hemo­
globin (9.4 ± 2.1 in TB, 14.3±1.7 in 
controls, p<0.001) was lower and the 
mean ferritin and transferring saturation 
were higher in the TB patients. Overall 
with time, serum ferritin levels decreased 
significantly and hemoglobin concentra­
tions increased significantly. Among the 
HIV-negative subjects, 20.2% of those 
without increased dietary iron had TB, 
while 44.8% of those with increased 
dietary iron had TB. Among the HIV-
positive subjects, 84.1% of those 
without increased dietary iron had TB 
while 71.4% of those with increased 
dietary iron had TB. After adjusting 
for age, HIV status, and liver function, 
increased dietary iron was associated 
with a 3.5 fold increased risk of devel­
oping TB and a 1.3 fold increase in risk 
of mortality. The authors conclude that 
elevated dietary iron may increase the 
risk of activating TB disease.89 Other 
confounding variables, such as regular 
alcohol consumption, also need to be 
considered. 
Effect of micronutrient 
supplementation on TB outcomes 
Data on the impact of micronutrient supple­
mentation on TB outcomes are currently 
limited. Three randomized trials were found 
in the literature and warrant special atten­
tion due to the strength of  their design: 
	 Vitamin A and Zinc: To investi­
gate the effect of vitamin A and zinc 
supplementation on anti-TB treatment, 
Karyadi et al. conducted a double-blind 
placebo-controlled trial among newly 
diagnosed pulmonary TB patients in 
Indonesia. Subjects received either 
1500 retinol equivalents (5000 IU) of 
vitamin A with 15mg zinc or placebo 
daily for six months. After two and six 
months, both groups had significant 
increases in hemoglobin and plasma 
retinol, but the increase in retinol was 
greater in the supplemented group. The 
proportions of patients with anemia 
or low plasma zinc or retinol were 
not different between groups. In both 
groups there was a significant increase 
in serum albumin and body weight, 
but the differences between groups 
were not significant. At two weeks and 
up until seven weeks, the number of 
patients with negative sputum smears 
in the micronutrient group was higher 
than the placebo group, as was the mean 
reduction in lesion area on the chest 
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x-ray. At six months, the Karnofsky of the inflammatory process. It should 
score of well-being was higher in the be noted that during the first two months 
micronutrient-supplemented group. The of anti-TB treatment and supplementa­
authors concluded that the supplemen­ tion, patients consumed a well balanced 
tation improved the effectiveness of diet while hospitalized, with no informa­
the anti-TB treatment in the first two tion on the diet quality after return to 
months of therapy, with less improve- home. Therefore the contribution of 
ment seen between two and six months 
of treatment. The major benefit is at 
dietary intake to short- and long-term 
results could not be assessed.88 
the community level because the patient 
would become less infectious sooner, 
with less opportunity to infect others.16 
 Multiple micronutrients: A random­
ized double-blind placebo-controlled 
trial was conducted among 530 patients 
 Iron: To investigate whether iron newly diagnosed with pulmonary TB in 
supplementation has a deleterious effect 
during active TB infection,90,91 Devi et al.
Tanzania to determine if micronutrient 
supplementation reduced conversion time 
conducted a prospective double-blind 
study of the effect of iron therapy on 
from sputum-positive to sputum-nega­
tive TB test results.92 The patients were 
moderately anemic (hemoglobin concen­ randomized to receive daily supplements 
tration 80-110g/L) adult male pulmo­ of either: (1) placebo, (2) 45mg elemental 
nary TB patients in India. Patients were zinc alone, (3) the same amount of zinc 
assigned to one of three groups for daily with multiple high doses of other micro-
supplementation and followed for six nutrients (5,000 IU vitamin A, 20mg 
months of TB treatment: (1) placebo, 
(2) 75mg elemental iron as ferrous 
fumarate, or (3) the same iron dose with 
each vitamin B1, and B2, 25mg vitamin 
B6, 50ug vitamin B12, 0.8mg folic acid, 
40mg niacin, 200mg vitamin C, 60mg 
added 25mg zinc, 2.5mg thiamine, 1.5mg 
riboflavin, 0.75 mg pyridoxine, 1.25mg 
vitamin E, 200 IU vitamin D3, 0.2mg 
selenium, 5mg copper), or (4) the same 
cyanocobalamin, 20mg ascorbic acid, and micronutrients without zinc. Sputum 
0.25mg folic acid. Significant increases in cultures were obtained at two, four, 
BMI, iron status, and other hematological and eight weeks of standard TB DOTS 
indices occurred in all three groups. The strategy therapy. The researchers did not 
highest increase in hemoglobin and iron find significant effects of micronutrient 
status occurred at one and two months or zinc supplementation on their primary 
in both supplemented groups compared outcome, culture conversion, at any time 
with the placebo group. This improved point, although they report that patients 
difference disappeared after six months receiving the zinc and multi-micronu­
of treatment, however. Radiological trient supplements had a 2.4kg higher 
and clinical improvement was similar weight gain than those receiving placebo, 
between groups. The authors concluded multi-micronutrients, or zinc alone (95% 
that in mild to moderately anemic TB 
patients, iron supplementation acceler-
CI 0.9, 3.8, p=0.002). The average weight 
gain overall was 6.88kg.92 The group 
ated the normal hematopoesis only in receiving zinc and multi-micronutrients 
the initial phases of treatment, possibly also had reduced mortality (RR 0.29; 95% 
because inflammation contributed CI 0.10, 0.80). Interestingly, among the 
towards anemia, and further improve­ HIV-co-infected group, zinc or micronu­
ment was dependent on the correction trients alone or together were associated 
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 with a 50-70% reduced risk of death, 
although this was not statistically signifi­
cant. The main limitation of the study 
was that supplement compliance was not 
ascertained. The authors conclude that 
high dose supplementation of multiple 
Micronutrients and TB Summary 
micronutrients may increase survival of 
HIV/TB co-infected patients during 
TB treatment, but that more research is 
needed in different settings among those 
with TB alone, and with differing nutrient 
doses depending on the location. 
	 The relationship between micronutrients and TB is complex. 
	 Active TB increases oxidative stress, creating higher demands for anti-oxidant nutrients. 
	 Depressed circulating levels of negative acute phase response nutrients may lead to overestimation 
of the role of micronutrients in TB disease. 
	 Limited studies suggest that for those with micronutrient deficiencies, daily micronutrient supple­
mentation may have an added benefit during early months of anti-TB therapy—to improve nutritional 
status, improve clinical treatment, and reduce mortality. 
	 For TB as with other infections, intake of iron beyond correcting iron deficiency may have deleterious 
effects and should be avoided. 
	 Pyridoxine supplementation (vitamin B6) should be provided with INH therapy in areas where diets 
are low in this vitamin. 
	 Supplementation with vitamin D may also be necessary where sunlight and diets are insufficient, 
although further research on the impact of vitamin D supplementation during TB treatment is 
needed. 
	 Additional research is warranted on the impact of multiple-micronutrient supplements on TB-associ­
ated outcomes in settings where local, predominantly cereal-based diets are unlikely to provide 
adequate micronutrient content (due to low bioavailability and high fiber content). 
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 V. Experience and considerations for 
    incorporating nutrition into TB programs 
Accessing and successfully completing TB 
treatment is complex. It involves diagnosis of 
illness and treatment over an extended period 
of time (usually 6-8 months) in individuals who 
are often poor, food insecure and face barriers 
to accessing health care. A common cause of 
TB treatment failure is poor adherence to the
lengthy treatment, resulting in TB drug resis­
tance. Multi-drug resistant TB is a serious chal­
lenge and growing concern in Africa. Social 
support is helpful in successful adherence.93 
Ideally, a TB control program will include a 
set of policies to educate, to motivate, and to 
watch patients.94 
Our review found that programmatic evidence
of nutritional support for TB patients is too 
limited to make firm recommendations for 
specific programs. However there is reason 
to believe that nutritional support could be
beneficial to disease management. Taking this 
reality into account and based on the evidence
review, nutritional support within TB programs 
may include the following components: 
	 Nutritional assessment to determine 
nutritional status and necessary referrals 
or intervention 
	 Nutrition education and counseling on 
symptom-management and improved 
dietary intake during and after TB treat­
ment and microbial cure 
	 Targeted micronutrient supplementation 
(e.g., vitamin B6) 
 Food support for treatment of malnutrition 
in TB and TB/HIV co-infected patients 
 Food support as a safety net program to 
increase treatment adherence 
There is little documentation to date on the
role of nutritional support within TB programs 
and thus it is uncertain whether any of these
components are actually being implemented 
on the ground. Most of the experience has 
been with the provision of food support to 
TB patients, and these lessons are summarized 
below. 
Experience providing food assistance to
TB patients 
Several TB control programs have provided 
food to TB patients and health care providers 
as a means to improve performance of each.95 
Food assistance is a potentially influential, 
targeted means for increasing adherence to TB 
treatment, reducing the costs to patients of 
staying in treatment, and improving nutritional 
status. Food assistance may influence early
case detection (encouraging patients to come
for diagnosis and treatment sooner in the
disease process), and promote the full course
of treatment. Both of these are important to 
decrease TB transmission.95 The economic
costs to those in TB treatment programs 
include loss of employment, income and 
productivity, increased travel cost to reach the
treatment centers, and other health-related 
costs. 93 Interventions that increase full treat­
ment adherence are important not only for the
patient, but for public health welfare. 
World Food Programme 
The World Food Programme (WFP), the food 
aid arm of the United Nations, has drafted 
a report summarizing food assistance in the
context of TB care. One goal of the WFP is to 
improve nutrition, quality of life, and self-help 
of individuals and communities. Their food 
assistance programs aim to enhance patient
adherence to treatment under DOTS (resulting 
in improved detection and cure rates), while
helping patients in food insecure households 
meet their nutrient needs during treatment. 
Food assistance increases health care center 
attendance thereby increasing case detection.93 
Feedback from WFP country offices indicates 
that food assistance motivates TB patients to 
remain on and complete treatment, improves 
their nutritional status, and encourages TB 
patients to participate in other health programs 
such as HIV/AIDS testing. Additional lessons 
are summarized in Box 6. 
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 Box 6. Experience from three WFP food-assisted TB programs93 
Lesotho Sudan Burkina Faso 
Setting Low TB treatment completion 
rate and high HIV prevalence 
Conflict setting Low TB detection rate and 
moderate HIV prevalence 
rate 
Partners Lesotho Ministry of Health 
and Social Welfare 
National TB Program 
TB Control Initiative “Horn of 
Africa” 
National TB Program 
Global Fund to fight HIV/ 
AIDS, TB, and Malaria 
Eligibility 
criteria 
Food insecurity 
Positive TB test (sputum or 
chest x-ray) 
Enrollment in DOTS strategy 
TB treatment program 
Vulnerability, 
Conflict in the area 
None 
Local 
assessment 
HIV is fueling TB epidemic, 
Male to female TB cases: 2: 
Displaced people with poor 
hygiene and malnutrition. 
Most patients with TB are 
food insecure and with poor 
nutritional status. 
Objective of food support 
is to increase attendance 
at testing and treatment 
centers, reduce default rate. 
Ration type Outpatient, monthly, 
distributed through health 
centers 
Family and patient portions 
Patient portions only Food provided to all TB 
patients and volunteers 
managing food distribution in 
health centers. 
Patient ration provided 
monthly. 
Ration 
content 
Family: 00g maize meal, 
60g pulses, 20g oil per 
person per day 
Patient: 200g corn soya 
blend (CSB) per day 
Patient: 0g CSB, 0g 
cereals, 0g pulses, 0g oil, 
0g salt, 2g sugar per day 
(2,226 kcal/day) 
Patient: .kg CSB, 2kg 
cereals, .kg pulses, 0.kg 
oil, 0.kg salt, 0.6kg sugar 
per person per month 
Reach 2,29 patients/month and 
18,953 indirect beneficiaries/ 
month 
,2 patients from 
January–August 200 
5,875 estimated beneficiaries 
for 2006 
Patient 
comments 
CSB helped them to gain 
weight quickly. 
Food assistance increased 
adherence to treatment. 
Improved well being. 
Food assistance increased 
adherence to treatment. 
Observation of increased 
attendance at health centers 
and decrease in number of 
defaulters. 
Problems 
encountered 
Health workers: hard to give 
away food but not receive 
incentive themselves. Difficult 
to integrate TB into HIV/AIDS 
treatment program. Difficulty 
with timely coordination 
between medication and food 
distribution. 
Health workers: hard to 
target beneficiaries since 
patients tend to deny illness 
and avoid treatment due to 
fear and stigma. 
Assessment not yet carried 
out. 
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Cost of providing food support 
Food supplementation may be considered 
an intervention targeted at overcoming 
barriers associated with continuing TB treat­
ment and also one that ensures that health 
services are tailored to the patient’s needs. 
If a significant number of persons do not 
complete treatment, then the health care 
system may be considered to have failed.94 
Data on the estimated numbers of patients 
with active TB that would benefit from 
nutritional support and the cost-effective­
ness of food support for TB patients are 
as yet unavailable. WFP estimated that 3.8 
million people affected by HIV were in need 
of nutritional support in 2006, and that 
nearly double that number will be in need 
by the year 2008. An estimated nine million 
Africans are co-infected with HIV and TB. 
These individuals are the most nutritionally 
vulnerable and many are likely to be in need 
of nutritional support. WFP and UNAIDS 
estimate that approximately $0.66 daily is 
required to support an AIDS patient and his/ 
her family, and most likely the cost would be 
the same for a patient with TB. Depending 
on the length of nutritional support during 
medical treatment, the theoretical cost of 
food support per patient would vary from 
approximately $40 for two months to $119 
for six months. The estimated medical costs 
to treat a person with active TB successfully 
vary considerably from country to country, 
from $140 in Uganda to more than $350 
per patient in Mozambique and Nigeria. 
Therefore, the cost of food support during 
treatment would require considerable addi­
tional resources.10 
Stop TB/World Bank 
A group from Stop TB/World Bank and 
Management Sciences for Health/Rational 
Pharmaceutical Management Plus/USAID 
completed a case study to examine the food 
assistance program in Cambodia, an area 
with high burdens of both TB and malnu­
trition. Although the direct impact of food 
assistance on TB case detection or treat­
ment success within the DOTS strategy 
program could not be determined, overall 
both patients and providers believed that the 
program benefits offset the costs of treat­
ment, motivated patients to seek treatment 
earlier, improved adherence to treatment 
and nutritional status, and reduced stress. 
Cured patients and their family members 
communicated the benefits of the program 
and promoted TB treatment within their 
communities. Patients reported that the 
monthly food ration lasted for two to nine 
days, depending on the household size and 
income. The group concluded that inte­
grating the food program into the DOTS 
strategy TB treatment program fits well 
within the Millennium Development Goals 
of poverty reduction, while promoting 
collaboration and demonstrating sustain-
ability and impact.95 
C-SAFE 
The Consortium for the Southern Africa 
Food Security Emergency (C-SAFE) 
provides food assistance to patients with 
HIV/AIDS, including those co-infected 
with TB. They conducted a literature review 
on the impact of targeted food assistance 
in people living with HIV/AIDS and 
field research in Malawi, Zambia, and 
Zimbabwe, but concluded that it is quite 
difficult to measure the impact of food aid 
within these programs due to very limited 
documentation. The most commonly 
reported measure of success across 
programs was increased treatment uptake 
and adherence. Based on anecdotal stories 
and testimonials, the authors report that 
individuals and families believed that the 
food aid increased the daily food intake of 
all household members, increased the money 
available for other needs, and improved 
household food security. These benefits 
were believed to result in improved weight 
and health, increased energy level, medical 
treatment adherence, school attendance, 
immunity, quality of life, productive ability, 
and survival—although objective measures 
of  these outcomes were limited.96 
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C-SAFE guidelines for the use of food aid for TB patients: 
 Work closely with all levels of the National TB Control Program to strengthen both referral mecha­
nisms/case-finding and monitoring and evaluation. 
 Ensure that patients receiving food are adhering to treatment plans. Checking of DOTS cards and 
spot-checking of clinic records should be included in the beneficiary verification protocol. 
 Provide food aid to eligible TB patients who are adhering to treatment for the entire length of the 
treatment. 
 Ensure provision of nutrient-dense, fortified commodities in food ration for at least the first two 
months of TB treatment (or entire treatment period if possible). 
 Discharge beneficiaries who fail to adhere to treatment plans. 
 Ensure that providers are well-informed about TB and are able to provide beneficiaries with simple 
advice, information, and encouragement. 
 Use every possible opportunity to disseminate information on TB to communities to encourage 
early case identification, treatment adherence, and HIV testing. 
 Deliberately link TB patients to long-term food security initiatives once they regain sufficient 
strength. 
 Discharge TB patients from food assistance upon completion of treatment, unless they remain 
chronically ill (in which case they should be transferred to another category). 
 Develop a recording system that identifies TB patients separately from other chronically ill benefi­
ciaries in order to track the success of this initiative. 
 Refer individuals to a different beneficiary category on a case-by-base basis as required. 
Source: C-Safe Learning Center. Targeted food assistance in the context of HIV 
Technical considerations for providing 
food assistance in TB programs 
To deliver an intervention that is effective 
in treating and controlling a life threatening 
disease such as TB, health care practitioners 
must work within the health care system that 
delivers care appropriate to people’s needs.94 
Although most evidence of the impact of 
food support on TB patients’ nutritional 
status, quality of life, and adherence to and 
outcome of treatment is anecdotal, there is 
strong reason to believe that such support 
will provide direct benefits to adults and 
children infected with TB as well as their 
families, during and following anti-TB 
therapy (See section III). 
With this in mind, it is possible to outline 
specific technical considerations for plan­
ning such support, including defining the 
objectives, assessing nutritional need (status, 
food insecurity), delivery channels, and other 
logistical considerations. For example: 
	 Questions to ask before getting 
started: Is food insecurity an issue for 
the target population? Is TB treatment 
adherence a challenge? Is TB program 
management strong? Who will be 
responsible for the design and manage­
ment of the food program? Are there 
mechanisms for procuring food and 
monitoring its distribution? Is there 
sufficient staff and time to do proper 
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nutritional assessments, to distribute which is sometimes necessary for take-
food, and to monitor program impact? home rations and where food insecurity 
Is there adequate and proper equipment affects the entire household. 
for measuring anthropometry? What 
training will be needed? 
 Duration of support: Most programs 
provide food support for the duration 
 Objectives: The objectives of food and of anti-TB treatment since assuring 
nutritional support should be clearly treatment adherence and completion 
articulated. Possible objectives include is a primary objective.93 However, in 
increased adherence to and completion some instances programs may wish to 
of anti-TB therapy, improved nutritional extend food support to assure adequate 
status, or reduced proportion of TB nutritional recovery following treatment 
patients who have BMI <18.5 at treat- completion. 
 
ment completion. 
Assessing nutritional need: Food 
support may be based on individual 
vulnerability to food insecurity or 
clinical evidence of malnutrition, or it 
may be based on household or commu­
 Food ration: The composition of a 
food assistance package will likely vary 
from country to country as there are 
no particular foods that are specifically 
recommended in the management of 
TB. Two models have been used: food 
nity vulnerability to food insecurity. In 
either case, baseline assessments of 
BMI (weight, height) or MUAC are 
by prescription (i.e., food is prescribed 
like a medicine for an individual) and 
food rations for the household. The 
recommended. If skin-fold thickness 
or bioelectric impedance analysis (BIA) 
is feasible then these measurements 
should be taken as well to assess body 
composition and degree of wasting. 
Understanding something about the 
most important considerations are that 
food should be palatable, nutrient dense, 
culturally appropriate, affordable, and 
available. There are, however, special 
considerations for therapeutic feeding 
that should be adhered to if that is the 
local diet is necessary in order to give 
timely and appropriate nutritional advice 
for patients presenting with appetite 
loss, nausea, or other symptoms related 
to infection and/or treatment. Need 
primary objective of food support. 
Most WFP-assisted programs provide 
household rations that include maize, 
pulses, vegetable oil, and corn-soya 
blend. Some sites include additional 
for micronutrient supplements can be 
ascertained based on knowledge of the 
local diet or on individual dietary risk 
items such as sugar, salt, rice, lentils, 
and fish. The overall food security situ­
ation will help determine whether the 
assessment. ration should be based on the individual 
 Delivery channels: Programs need 
to decide where food will be delivered 
or household. Frequently the patient 
who is receiving the individual ration 
and if food support will be “directly 
observed” (on-site, cooked) or provided 
for home consumption (usually raw 
ingredients). Programs also need to 
determine whether rations will be made 
will share it with other family members, 
resulting in an inadequate amount of 
nutritional support for the patient. 
Household rations, therefore, may help 
maintain the productivity and income 
available to TB patients only, which is 
easier to do with on-site feeding, or made 
available to other household members, 
generating ability of other household 
members, indirectly benefiting the 
patient as well.93 
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	 Monitoring and evaluation: The 
indicators used to monitor and evaluate 
the effectiveness of the food assistance 
program are usually TB specific: cure 
rate, death rate, and default rate.96,93 
Additional social markers of quality of 
life, well-being, and health center atten­
dance before and after the program is 
initiated may help evaluate its impact as 
well. Repeated weight, skin-fold thick­
nesses, and BMI measurements should 
also be considered for routine moni­
toring and recording.96 Since nutritional 
status is related to TB treatment as well 
as to food intake, it may be difficult to 
distinguish whether improvement in 
nutritional status is due to control of 
the disease or to improved food intake 
supplied by the food assistance program. 
(Additional information on indicators is 
provided in the next section.) 
	 Procurement and distribution: 
Procurement and distribution of food 
rations are major challenges for food 
support programs. Program managers 
should determine where they can obtain 
a reliable source of food and which 
delivery option(s) they will implement. 
These may include: (1) food and medi­
cine delivered to patient at the same time, 
with directly observed therapy; (2) food 
delivered on a fixed day, different from 
medicine delivery; or (3) food delivered 
weekly or every two weeks for on-site 
or take-home feeding. At some facilities 
staff make up individual food packets; 
at others, the patients apportion and 
distribute the food among themselves 
according to ration guidelines. The food 
can be delivered to the patient from 
health care facilities, from a local store, 
or other delivery points. Flexibility in 
food delivery to patients helps providers 
adapt to local conditions.95 Reporting 
systems, training, and supervision are 
essential to limit misuse and to track the 
number of participants served. Issuance 
and use of food prescriptions or ration 
cards should be required before food is 
distributed to individuals.95, 96 
	 Other management issues: A 
successful food assistance program can 
serve large numbers of TB patients, and 
is feasible and sustainable within a strong 
TB control program, as long as atten­
tion is paid to transparent management 
systems, communication, and problem 
solving capacity across all stakeholders 
including ministries of health, funders, 
communities, and patients.93 Cost-effec­
tiveness will need to be measured. 
Assessing the impact of food support 
Practical tools to assess the impact of food 
assistance are not commonly available and 
experience with impact evaluation is still 
lacking in most food-assisted programs.96 
However, below are some suggested indi­
cators for measuring the impact of food 
assistance based on experience and expert 
opinion: 
	 Nutrition: Traditional quantitative 
measurements to assess nutritional status 
at the beginning and during the program 
include anthropometric measurements 
such as height, weight, BMI and MUAC. 
Little is known about the sensitivity and 
specificity of these measures to monitor 
changes in nutritional status in TB (and 
TB/HIV co-infected) patients receiving 
food support during treatment, and 
more study is needed to determine their 
utility. Therefore, anthropometric assess­
ment may be most helpful in measuring 
program impact when used in conjunc­
tion with other measures.96 
	 Strength and stamina: Handgrip 
strength (using a handgrip dynamom­
eter) could be used to measure change 
in strength but, like anthropometry, has 
not been tested in TB patients. Handgrip 
strength correlates to BMI and MUAC 
and is a relatively new tool for use as 
a proxy measurement of nutritional 
status.96 
	 Treatment uptake and efficacy: This 
is the number of patients coming for 
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diagnosis and successfully completing patients, including adults and children) 
treatment. The TB cure rate, death rate, during and after TB treatment; (2) TB 
and default rate should also be reported. treatment outcome; and (3) survival. 
Uptake of other services, such as HIV  The most effective formulation, dura-
testing, can also be measured. tion, and impact of micronutrient supple-
Quality of life: Food support may  ments, in addition to anti-TB treatment, 
have a positive impact on quality of life, to improve: (1) nutritional status; (2) TB 
but there are no published studies that treatment outcome; and (3) survival in 
directly examine the impact of food persons with TB (including those with 
supplementation on quality of life in TB/HIV co-infection). 
TB.96 Quality of life can be measured  The effect of nutrition education 
with several different tools, such as the focusing on nutrient-rich food cultiva-
Karnofsky score. The impact of food tion and consumption, on the nutritional 
support can also be assessed in relation to status of TB patients, their recovery, and 
social and psychological considerations. on their families. 
Household food security: Even   Non-nutritional benefits of nutritional 
though a food assistance program may support in TB and TB/HIV co-infected 
target an individual, it also directly patients and programs on increased TB 
impacts all household members. Many case detection, treatment adherence, and 
programs provide household rations. outcome of treatment (e.g., in relation 
Impact at the household level, however, to re-emergence of TB disease and inci­
is not necessarily the same as impact on dence of other infections, particularly in 
the targeted household member, and children). 
may warrant specific monitoring and  Other non-nutritional benefits of nutri­
evaluation. Indicators of household tional support in TB and TB/HIV co­
food security include dietary diversity, infection including on quality of life, 
number of meals consumed daily, diet physical activity and endurance, and 
changes, frequency of hunger and lack improved socioeconomic benefit with 
of food in the household, consump­ sooner ability to return to work. 
tion of “luxury” foods, expenditures on 
food, and asset retention. 
 Screening for vitamin D deficiency in 
newly diagnosed TB patients to deter-
Research priorities mine prevalence of the condition and 
relationship with TB. 
Although the inter-relationship between 
nutritional status and TB disease is well 
documented, many areas require further 
investigation to improve understanding and 
 Trials of vitamin D supplementation to 
determine the link between vitamin D3 
deficiency and susceptibility to active 
TB disease. 
management of malnutrition in TB. Specific 
priorities that have emerged from this review 
include studies of: 
 Successful models for integrating nutri­
tional support in TB and TB/HIV 
programs, including collaboration 
The effect of generalized malnutrition  between programs to achieve shared 
and micronutrient deficiency on TB goals of  successful treatment. 
treatment outcomes.  Best practices for nutrition assessment, 
The most effective formulation (nutri­ referral, and protocols for treating 
tional profile) and duration of food malnutrition in adults and children in 
support—taking into consideration local TB and TB/HIV programs. 
diets and food availability—for treating  The cost-effectiveness of food and 
malnutrition and improving: (1) overall 
nutritional status (muscle mass in TB 
nutritional support within TB and TB/ 
HIV programs. 
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Conclusion
 
Based on the information summarized in 
this report, it is clear that TB affects nutri­
tional status. Many patients with active TB 
experience severe weight loss and some 
show signs of vitamin and mineral deficien­
cies. Persons with TB/HIV co-infection 
are even worse off nutritionally. However, 
the evidence surrounding best practices for 
nutritional management is very limited. 
Some TB control programs have provided 
food to both TB patients and health care 
providers as a means to improve perfor­
mance of each. Food assistance is a poten­
tially influential means for increasing adher­
ence to TB treatment, reducing the costs 
to patients of staying in treatment, and for 
improving nutritional status. Although most 
evidence of the impact of food support on 
TB patients’ nutritional status, quality of life, 
treatment adherence, and outcome is anec­
dotal, there is reason to believe that such 
support will provide direct benefits to adults 
and children infected with TB both during 
and following drug therapy. However, the 
cost to programs of providing food support 
may be considerable. Other low-cost inter­
ventions such as periodic nutritional assess­
ment and counseling on diet, and nutritional 
management of symptoms and drug-side 
effects, may help TB patients to maintain 
or increase their food intake and adhere to 
TB medications. But again, program and/or 
research evidence is limited. 
Many areas require further investigation to 
improve our understanding and manage­
ment of malnutrition in TB and TB/HIV 
co-infection. Of particular priority are 
studies of the most effective approaches for 
treating malnutrition and improving overall 
nutritional status and muscle mass in TB 
and TB/HIV co-infected adults and chil­
dren during and after TB treatment—taking 
into consideration local diets and food 
availability. Successful and varied models 
for integrating nutritional support into TB 
and TB/HIV programs and data on the 
cost-effectiveness of integrated nutritional 
support are also needed. 
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ANNEX 1: Body Mass Index in HIV-positive and HIV-negative patients with newly diagnosed 
tuberculosis 
BMI kg/m2 Mean ± SD 
Reference, location Men Women 
HIV+ 
(n) 
HIV­
(n) 
p value HIV+ 
(n) 
HIV­
(n) 
p value 
Van Lettow 
Malawi 
. ± 2. 
(00) 
.6 ± 2. 
(9) 
NS . ± 2.9 
(6) 
. ± 2. 
() 
NS 
Van Lettow9 
Malawi 
. ± 2.6 
(6) 
. ± . 
() 
NS . ± 2. 
(2) 
.6 ± 2. 
(9) 
NS 
Villamor6 
Tanzania 
9.0 ± 2. 
(6) 
.9 ± 2.2 
(69) 
NS 9. ± . 
() 
9. ± .0 
(2) 
NS 
Niyongabo 
Burundi 
.6 ± . 
(0) 
M:F .6 
. ± 2. 
() 
M:F 0. 
0.0 
Kennedy6 
Tanzania 
6.6 ± . 
(2) 
.6 ± . 
(6) 
<0.0 .2 ± 2. 
(2) 
.6 ± .9 
(2) 
NS 
Mugusi69 
Tanzania 
. ± 2.6 
(6) 
M:F 0.6 
.6 ± .2 
(9) 
M:F . 
NS 
Mabedo6 
Ethiopia 
6. ± 2. 
(2) 
M:F 2. 
6.6 ± 2. 
(00) 
M:F 2. 
Kassu9 
Ethiopia 
. ± 2. 
() 
M:F 0. 
.0 ± 2. 
() 
M:F 0.2 
NS 
Paton6 
Singapore 
. ± 2. 
() 
. ± . 
(0) 
NS 
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ANNEX 2: Summary of studies investigating micronutrient status of patients with 
pulmonary tuberculosis 
Nutrient Subjects/study type Findings Reference 
Vitamin B6 20 TB patients 90% with low B6 at initiation of Visser, 2000 
(pyridoxine) Longitudinal (one week therapy, 100% patients ↓ B6 
South Africa before and after initiation of 
TB treatment) 
concentration significantly at one 
week 
Vitamin A 
Rwanda 
9 TB/HIV+ patients 
Cross sectional 
29% vitamin A deficient 
Limitation: no healthy control group, 
no acute phase response control 
Rwangabwoba, 
999 
Vitamin A  TB patients % of TB patients with marginal Ramachandran, 
India 6 healthy household 
controls 
0 health “normal” controls 
Longitudinal 
vitamin A status at baseline 
↓ Mean vitamin A in TB patients 
versus household or normal controls 
↑ Mean vitamin A in TB patients at 
six months 
Limitation: no acute phase 
response control 
2000 
Vitamin A, Pulmonary TB patients ↓ Mean vitamin A, hemoglobin, Mugusi, 20069 
hemoglobin, albumin (9 HIV-, 6 HIV+) albumin in all TB patients compared 
Tanzania  blood donor TB- 
controls 
(99 HIV-,  HIV+) 
Longitudinal (two months) 
with controls; lowest in TB/HIV 
patients 
↑ Vitamin A deficiency in
TB/HIV patients 
↑ Mean vitamin A, hemoglobin, 
albumin in TB/HIV- at two mo, no 
change in TB/HIV+ patients 
Limitation: no acute phase 
response control 
Vitamin A, Vitamin Pulmonary TB patients ↓ Mean vitamin A, C and E, Mabedo, 2006 
C, Vitamin E, (00 HIV-, 2 HIV+) hematocrit, albumin in TB patients 
hematocrit, albumin  Ethiopian healthy versus controls 
Ethiopia controls 
Cross-sectional 
Vitamin A, E, ferritin, 
hemoglobin, zinc, 
selenium 
Malawi 
0 TB/HIV+ patients 
0 TB/HIV- patients 
↓ Mean hemoglobin in TB/HIV+ 
patients, 
↑ Prevalence of anemia compared to 
TB/HIV- patients, 
↑ Mean ferritin in TB/HIV+ patients 
compared to TB/HIV- patients, 
59% of all deficient in vitamin A 
12% of all deficient in vitamin E 
80% of all deficient in zinc 
88% of all deficient in selenium 
Van Lettow, 200 
            
 
 
 
 
Vitamin A, 
hemoglobin, zinc, 
albumin 
Indonesia 
 TB patients 
 healthy controls 
Cross-sectional 
↓ Mean vitamin A, hemoglobin, 
zinc, albumin in TB patients versus 
controls 
↑ Prevalence of anemia, vitamin A
and zinc deficiency in TB patients 
Karyadi, 2000 
Vitamin C, Vitamin E 
India 
0 TB patients 
0 healthy controls; 
Cross-sectional 
↓ Mean vitamin C and E in TB 
patients versus controls 
Vijayamalini, 
200 
Vitamin C 
Russia 
9 TB patients, 
20 healthy controls 
all participants smoked; 
Cross-sectional 
↓ Mean vitamin C in TB patients 
versus controls 
Bakaev, 2002 
Iron 
Zimbabwe 
9 TB patients (69 HIV+, 
9 HIV-) 
9 ( HIV+,  HIV-) 
controls, matched for age 
and sex 
Longitudinal (seven to nine 
months) 
↑ Mean ferritin and transferring 
saturation in TB patients compared 
with controls 
↓ Mean hemoglobin in TB patients, 
lowest in TB/HIV+ patients 
↑ Mean hemoglobin in all patients 
Gangaidzo, 2009 
Copper, zinc, 
selenium, iron 
Ethiopia 
 TB patients ( HIV+, 
 HIV-) 
 healthy controls 
Longitudinal 
↑ Mean copper in all TB patients 
compared with controls 
↓ Mean zinc in TB/HIV+ patients 
compared to TB/HIV- and controls 
↓ Mean selenium in TB/HIV+ 
patients compared to TB/HIV- and 
controls 
↓ Mean iron in TB/HIV+ patients 
compared to controls 
After two mo of therapy, ↓ Mean 
copper, no change in selenium and 
iron, ↑ Mean zinc in TB/HIV- but no 
change in HIV+ 
Kassu, 2009 
Vitamin D 
England 
26 TB patients 
6 healthy controls 
26% prevalence vitamin D deficiency 
Vitamin D deficiency associated with 
active TB (OR 2.9; 9% CI .-6.) 
Wilkinson , 2000 
Vitamin D 
England 
20 TB patients foreign 
born 
76% prevalence vitamin D deficiency Ustianowski, 
200 
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